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palavras-chave           Anti-solvente, cristalização, escala micro, operação em contínuo,vitamina D3 
 
resumo A vitamina D3 é um micronutriente essencial para o metabolismo do cálcio, 
sendo esta maioritariamente sintetizada na pele do ser humano, quando 
exposta a radiação UVB. Contudo, inúmeros factores têm vindo a reduzir a 
nossa exposição à luz solar, diminuindo assim os níveis de vitamina D3 no 
corpo humano a nível global e aumentando a preocupação por parte de 
diversas instituições médicas a nível mundial. Para superar esta deficiência 
em vitamina, a vitamina D3 tem sido adicionada à alimentação humana 
através de alimentos fortificados e de suplementos alimentares. Para 
satisfazer a procura da população em vitamina D3, este trabalho apresenta 
uma unidade de cristalização com dois estágios que opera em contínuo à 
escala micro. O objectivo deste trabalho é projectar e optimizar esta unidade 
de cristalização por forma a desenvolver uma unidade de produção de cristais 
de vitamina D3 mais económica, mais sustentável, e com elevado rendimento 
de cristais aproriados para aplicações farmacêuticas. 
  
 O primiero estágio da unidade de cristalização projetada corresponde a uma 
coluna de vidro onde a nucleação é intensificada através de cristalização por 
evaporação e por adição de anti-solvente. Este cristalizador opera a 40 ºC e 
o caudal volumétrico é controlado manualmente. O segundo estágio é um 
cristalizador tubular onde a cristalização ocorre por redução da temperatura 
para promover o crescimento dos núcleos produzidos no estágio anterior. 
Esta é operada a 7 ºC e em 59 s de tempo de residência. Após o segundo 
estágio, um filtro está integrado no sistema para recolher os cristais de 
vitamina D3 sintetizados.  
 
Este trabalho está dividido em duas partes. A primeira abrange a optimização 
da unidade de cristalização, a qual foi conseguida estudando o efeito da razão 
volúmica entre o anti-solvente e o solvente no desempenho da cristalização. 
O melhor resultado foi obtido para a proporção volúmica de 3, a qual permitiu 
alcançar 52 % de rendimento absoluto e 60 % de eficiência de filtração. 
Adicionalmente, por forma a melhorar o rendimento e a eficiência de filtração, 
ensaios experimentais foram realizados onde a corrente de permeado (da 
filtração) foi reciclada. Porém, as melhorias esperadas não se verificaram, o 
que significa que ensaios experimentais adicionais são necessários para 
sustentar uma conclusão sólida relativamente ao efeito do reciclo no processo 
em estudo. A reprodutibilidade do processo desenvolvido e optimizado 
também necessita  ser melhorada. 
  
   A segunda parte corresponde à caracterização dos cristais de vitamina D3 
produzidos durante os ensaios de optimização. Os cristais apresentam uma 
forma prismática e aglomeração significativa. A distribuição de tamanhos dos 
cristais é ampla, extendendo-se desde, aproximadamente, 0.25 μm a quase 
500 μm. Adicionalmente, a estrutura dos cristais produzidos não corresponde 
à estrutura termodinamicamente mais estável. Excluindo o seu hábito, as 
características dos cristais produzidos não são adequadas para aplicações 
na indústria farmacêutica. No entanto, sugestões são apresentadas para 
melhorar ambas as características dos cristais e a optimização do processo.
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abstract Vitamin D3 is an essential micronutrient for calcium metabolism, which is mainly 
synthesized in the skin of the human organism when irradiated with UVB light. 
However, a variety of factors have been reducing our exposition to sunlight, 
and thus the levels of vitamin D3 in the body have been decreasing, rising the 
concern of numerous medical institutions worldwide. To overcome such 
vitamin deficiency, the vitamin D3 has been added to the diet through fortified 
food and dietary supplements. To address the population demands on vitamin 
D3, this project presents a two-stage crystallization unit that operates 
continuously at a microscale. The aim of this project is to design and optimize 
this crystallization unit in order to develop an economical and sustainable high 
yield production unit of vitamin D3 crystals suitable for subsequent 
pharmaceutical applications. 
 
The first stage of the designed crystallization unit corresponds to a glass 
column where nucleation is enhanced by evaporation and anti-solvent 
crystallization. This crystallizer operates at 40 ºC and the volumetric flow rate 
is manipulated manually. The second stage is a tubular crystallizer where a 
cooling crystallization takes place to further grow the nuclei generated in the 
previous step; it is carried out at 7 ºC and 59 s of residence time. At the end of 
the second stage, a filter is placed to collect the synthesized vitamin D3 crystals. 
 
This work is divided in two main parts. The first part comprehends the 
optimization of the crystallization unit, which was accomplished by studying the 
influence of the anti-solvent/solvent volumes ratio on the performance of the 
crystallization. The best results were obtained for the volume ratio of 3, where 
52 % of absolute yield was achieved as well as 60 % of filter efficiency. 
Furthermore, other experiments were performed where the permeate stream 
(of the filtration) was recycled to improve both yield and filter efficiency. 
However, such expected improvements were not confirmed, which means that 
additional experiments are needed to support any reliable conclusion regarding 
the effect of recycling on the process. The reproducibility of the crystallization 
process developed and optimized needs to be improved as well.  
 
The second part corresponds to the characterization of the crystals produced 
during the optimization assays. The crystals exhibit a prismatic habit and a 
significant degree of agglomeration. The crystal size distribution is large, 
extending from ca. 0.25 μm to almost 500 μm. Furthermore, the obtained solid-
state form is not the thermodynamically stable one. Besides the crystal habit, 
the properties of the obtained crystals are not yet suitable for a pharmaceutical 
application. Nonetheless, suggestions of improvement are presented for both 
crystals characterization and optimization of the crystallization process. 
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Chapter 1  
INTRODUCTION 
 
Start where you are. Use what you have. Do what you can. 
Arthur Ashe 
  
This chapter introduces the theoretical background of this research and contextualizes the 
problem of this research work. Furthermore, it presents the objectives of this research as well as the 
structure of the thesis.  
 
1.1. Vitamin D 
Vitamins are nutrients needed in small doses and are not produced by the organism of a 
human being. Therefore, they need to be obtained through the diet. [1] Vitamin D is a fat-soluble 
steroid that comprises a group of molecules called calciferols. The most addressed calciferols for the 
human body are ergocalciferol and cholecalciferol, commonly known as Vitamin D2 and Vitamin 
D3, respectively. [2]  
Vitamin D3 is mainly obtained through a photochemical reaction induced by the sunlight 
adsorbed in the skin. The compound 7-dehydrocholesterol, present in the basal and suprabasal layers 
of the epidermis, when exposed to ultraviolet B radiation, UVB, produces previtamin D3. The later 
undergoes a process that includes thermal isomerization from which vitamin D3 is produced. Vitamin 
D3 is not biologically active until enzymes functionalize it. Therefore, in the liver, vitamin D3 will 
be transformed in 25-hydroxycholecalciferol, also called 25-hydroxyvitamin D3. Further 
hydroxylation in the kidney will convert 25-hydroxycholecalciferol into 1,25-
dihydroxycholecalciferol (see Figure 1.1). This compound is an endogenous hormone that regulates 
the calcium uptake in the intestines and the calcium levels in the bones and kidney. [1] [2]  
Vitamin D2 is a plant-derived micronutrient which is produced in a similar way of vitamin 
D3. Moreover, vitamin D2 is also converted into a hormone named as 1,25-hydroxyergocalciferol, or 
1,25-hydroxyvitamin D2. Both vitamins possess similar chemical structure and biological action. 
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However, vitamin D3 has been reported in many studies to be superior to vitamin D2 due to its higher 
bioavailability. [2] 
 
 
Figure 1.1 Scheme of vitamin D3 production in the skin and further transformation into the endogenous 
hormone 1,25-dihydrocholecalciferol. [1] 
 
Besides its synthesis in the human body, vitamin D3 can also be obtained by the diet. The 
main naturally produced dietary sources of Vitamin D3 are animal food products. Examples are fat 
fishes and fish liver oils, which have the highest content in Vitamin D3 (see Table 1.1). Vitamin D2 
has the highest content in wild grown mushrooms. However, the most commercialized mushrooms, 
the white button mushroom, have a very low level of that vitamin (see Table 1.1). Some producers 
even irradiate those mushrooms with UVB light to increase its content in vitamin D2. Vitamin D can 
also be found in eggs and in dairy products, such as cheese and butter. [2] 
Both healthy diet and daily exposition to sunlight are necessary to reach the daily levels of 
vitamin D required by the human body. The vitamin D status of a human being can be evaluated by 
measuring the serum concentration of 25-hydroxyvitamin D. This substance is the main circulating 
form of vitamin D and it is used as a biomarker because it reflects the dietary intake of both vitamin 
D2 and D3, and the production of the endogenous hormone from vitamin D3. [2] Lips and his 
colleagues have defined four different levels for the concentration of 25-hydroxyvitamin D in the 
human’s blood (see Table 1.2). [3] Different institutions did not agree with the classification of 50 
nmol L-1 as repletion level. The Institute of Medicine, IOM, has stated that 50 nmol L-1 should be 
defined as the concentration at which 97,5 % of the vitamin D in need would be covered. On the 
Chapter 1 Introduction 
3 
 
other hand, the Endocrine Society, ES, has stated that the repletion level should start at 75 nmol L-1 
rather than 50 nmol L-1. [2] 
 
Table 1.1 Vitamin D content of different food products. [2] 
  Range 
  μg Vitamin D per 100 g 
Raw products   
Fish Salmon 4.2 – 34.5 
Perch 0.3 – 25.2 
Tuna 1.7 – 18.7 
Cod 0.5 – 6.9 
Mushrooms Wild grown mushrooms 0.3 – 29.8 
White bottom mushrooms 0 – 0.2 
Animal products Pork meat 0.1 – 0.7 
Chicken meat 0 – 0.3 
Beef Liver 0 – 14.1 
Eggs 0.4 – 12.1 
Processed foods   
Fish Tuna liver oil 144,400 
Cod liver oil 137.5 – 575.0 
Canned sardines 3.2 - 10 
Mushrooms Irradiated Mushrooms 6.6 – 77.4 
Dairy products Butter 0.2 – 2.0 
Cheese 0 – 0.1 
 
Table 1.2 Classification of the concentration of 25-hydroxyvitamin D in the human’s blood. [3] 
Concentration  
(nmol L-1) 
Classification 
< 12.5 Severe deficiency 
12.5  – 25 Deficiency 
25 – 50 Insufficiency 
>50 Repletion 
 
The importance of keeping the levels of vitamin D superior to 75 nmol L-1 is essential for the 
bone metabolism. This vitamin is a key for a healthy bone development and reduces the risk of bone 
diseases like osteoporosis and rickets. [2] Furthermore, Grant and colleagues have reported the 
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benefits of vitamin D, well supported by research, in reducing the risk of many other diseases, such 
as cardiovascular diseases and cancer [4] (see Figure 1.2). 
 
 
Figure 1.2 Benefits of optimal levels of Vitamin D for the human being. [4] 
 
As a consequence of the dimension in the human body of the vitamin D impact, this 
compound can additionally improve the health economics of a country. Grant determined that a rise 
of 40 nmol L-1 in vitamin D levels would help save up to 16.7 % of health care costs. [4] 
 
1.2. Deficiency of Vitamin D3 
 Many organizations have identified vitamin D deficiency or insufficiency as a public health 
problem that has grown worldwide. [2] In fact, the International Osteoporosis Foundation, IOF, has 
developed a global vitamin D map to expose this problem. This map is a result of an extensive review 
of worldwide 25-hydroxyvitamin D plasma levels available in reliable published publications. In 
2014, from an analysis of this map, Hilger has shown that 6.7 % of the overall population presented 
25-hydroxyvitamin D levels below 25 nmol L-1, 37.3 % below 50 nmol L-1 and only 11.9 % of the 
population exhibited levels above 75 nmol L-1. [2] [5] 
Many reasons can be associated to this worldwide vitamin D deficiency. To begin with, 
malnutrition, a condition where the diet does not match to provide the adequate level of vitamin D. 
Furthermore, the level of this vitamin is also dependent on the solar UVB radiation that reaches the 
skin. This changes with geographic latitude, season of the year and time of the day. Currently, other 
factors help reducing the exposition of the skin to sunlight. Those are severe air pollution in large 
cities, less outdoor activity as a consequence of an unhealthy life style change, and topical application 
of sunscreen with high sun protection factors. [2] The latter is a result of the intense solar radiation 
that can promote skin cancer, among other diseases. Consequently, exposition to sunlight must be 
moderated but regular to promote vitamin D synthesis. [2] [6] The immobility of elderly population 
-20%
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-20%
Cardiovascular diseases
-25%
Diabetes
-25%
Cancer & others
-34%
Falling in elderly
-50%
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compromises their vitamin D levels as well as the decline of 7-dehydrocholesterol characteristic of 
aging. [2] 
As the main source of vitamin D, more specifically vitamin D3, is being compromised, there 
is a need to improve vitamin D status worldwide by food fortification, or dietary supplements. Some 
countries have already taken measures to adjust the national recommendations for dietary intake of 
vitamin D. For example, the United States increased the daily intake for children since the first days 
of life. In 2008, the American Academy of Pediatrics increased the level for 400 IU and in 2010 the 
IOM increased it for 600 IU. In 2012, medical organizations from Germany, Austria and Switzerland 
also increased the recommended daily vitamin D intake to 800 IU for all age groups starting from 1 
year of age. [2] Currently, Finland has already eradicated vitamin D deficiency due to mandatory 
food fortification. The first targets were children and adolescents by increasing the content of vitamin 
D in most milks, sour milks and yogurts. [7] 
 
1.3. Industrial production of Vitamin D3 
To accomplish the goals established by different countries and to overcome the deficiency 
of vitamin D, this compound needs to be produced industrially as a pure crystalline vitamin. 
Currently, it is difficult to know how is being developed the production of vitamin D3 due to the 
competitive nature of the market. [8] Nevertheless, it has been found a process diagram of vitamin 
D3 manufacture process, dated from 1999 (see Figure 1.3). [9] 
 
 
Figure 1.3 Flow diagram of the manufacturing process of vitamin D3. [9] 
 
As it can be seen, there are two stages in the production of the vitamin D3, reaction stage and 
isolation stage. During the first one, 7-dehydrocholesterol is dissolved in an appropriate solvent, such 
as free peroxide diethyl ether, and then pumped to a UV-transparent reactor where the photochemical 
reaction is promoted. The second stage starts with the evaporation of the solvent of the outlet stream. 
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The latter is made of unconverted reactant, pre-vitamin D3, vitamin D3 and irradiation by-products. 
While the ether is being removed, another solvent is added to the mixture to promote the 
crystallization of the reactant in the next vessel. After the crystallization, that solvent is removed also 
by evaporation obtaining at the end vitamin D3 in a resin form. [9] This resin form is mainly used for 
supplementation of animal feeds. Concerning vitamin D3 for human consumption, in 2012, there was 
still no crystalline vitamin D3 form that was approved by U.S Food Drug Administration, FDA. [8] 
The separation and purification of vitamin D3 is quite difficult. The resin is often subject to an 
expansive low yield chemical complexation. [9] 
Despite these challenges reported from 1999, the vitamin D3 market is expected to reach $2.5 
Billion by 2020. [10] The key players in this market, such as Nestlé S.A. (Switzerland), Koninklijke 
DSM N.V. (The Netherlands), among others, are focusing on the expansion of their facilities and 
investing in R&D activities to gain a competitive edge through new product developments. [10] 
 
1.4. Objectives of the Thesis 
The project named “Microprocessing photovitamin D3 using photo-high-temperature 
intensification” has been developed to satisfy the worldwide need of pure crystalline vitamin D3 
suitable for pharmaceutical and food applications. That project aims to design an economical and 
sustainable high yield production unit for vitamin D3. The production unit under development is 
divided in three operation steps: synthesis of vitamin D3, purification of the synthesis outlet stream 
and vitamin D3 crystallization.  
The work of this thesis is related with the last step of the unit, the vitamin D3 crystallization. 
This study aims to optimize the crystallization process through a microscale continuous flow 
operation, which enhances mass and heat transfer, and process control, as well as increases material 
throughput in lower residence time. Furthermore, this project aims to characterize the vitamin D3 
crystals synthesized in order to assess their applicability in pharmaceutical industry. 
  
1.5. Outline of the Thesis 
This thesis is organized in four parts. The first part, which corresponds to the second chapter, 
is a literature review where it is described the phenomenon of crystallization, are presented the 
advantages of a continuous crystallization in a sub-millimeter scale and is approached the 
characterization of crystals. Furthermore, there is a chapter where one describes the methods applied 
to achieve the goals of this thesis. The forth chapter is a sequence of the previous one, where the 
results are presented and discussed. Last but not the least, there is a chapter dedicated to the 
conclusions of this report where are highlighted the possible improvements in this study. 
  
Chapter 2 
LITERATURE REVIEW 
 
Nothing in life is to be feared, it is only to be understood.  
Now is the time to understand more, so that we may fear less. 
Marie Curie 
 
The study developed is essentially based on the separation technique of crystallization. 
Therefore, this chapter initially presents a literature survey to clarify the fundamentals behind a 
crystallization phenomenon. This chapter will start with a general approach of crystallization and 
will grow further in crystallization from solution. Furthermore, this review will present a subchapter 
where it is discussed the operation mode of crystallization, continuous operation at a micro scale. 
 
 Crystallization 
Crystallization is one of the oldest separation processes known by mankind. As an example, 
crystallization is the method responsible for the collection of sodium chloride crystals via evaporation 
of seawater. Scientifically crystallization is defined as “the phase transformation of a compound from 
a fluid or an amorphous solid state to a crystalline solid state”. [11] The crystalline solid state, also 
known as crystal, is ideally a pure three-dimensional ordered structure. The latter is stablished by 
forces at the molecular level actuating during crystallization. [12] 
Crystallization is based on a phase change of at least one of the compounds of a mixture. 
Therefore, the phase diagram of the mixture is an important tool to better understand and operate the 
system. Depending on the phase diagram, different crystallization methods can be applied (see Figure 
2.1). [11] [13] For example, Figure 2.1(c) describes the thermodynamic behavior of a compound 
easily crystallized from an inert gas phase without going through a liquid phase. That method is 
called crystallization from a vapor or desublimation. Melt crystallization is a method mostly applied 
to eutectic-forming systems (see Figure 2.1(b)). Eutectic is the composition of a binary liquid mixture 
where both compounds solidify at a specific temperature. Under that temperature, the compounds 
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are theoretically obtained as pure solids. Melt is the name given to a eutectic-forming system as a 
homogeneous liquid phase. [14] Melt crystallization is mainly used as a purification operation due 
to high purity values achieved within this process, values close to 99.9 %. Figure 2.1(a) presents 
solubility curves of different compounds in an aqueous system. That phase diagram is the most 
suitable for the method called crystallization from solution. When this process is applied, highly pure 
crystals can be produce in a single crystallization stage, unlike melt crystallization. [13]  
 
 
(a)                                                             (c) 
 
Figure 2.1 Phase diagrams characteristic of different crystallization systems: (a) Solubility curves of diverse 
aqueous systems suitable for crystallization from solution; (b) Eutectic-forming system of ortho- and para-
chloronitrobenzene suitable for melt crystallization; (c) Phase diagram of naphthalene, a compound suitable 
for vapor crystallization. [14]  
 
 Crystallization from solution 
Figure 2.2. presents a solubility curve, cs. As mentioned in the previous section, that phase 
diagram is the most suitable for crystallization from solution. A solution is a homogeneous phase 
mixture of two or more compounds. The most abundant compound is generally called solvent and 
the remaining are called solutes. For a temperature T1, when the solute concentration in the solution 
is equal to point a (see Figure 2.2), the solution is said to be undersaturated. In this condition, the 
(b) 
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solid phase is always dissolved in the solvent, and the solution is always homogeneous. [13] [14] 
[15] 
 
Figure 2.2 Representation of a crystallization from solution phase diagram where both solubility curve, cs, 
and metastable limit, cm, are presented. [14] 
 
If the concentration of the solute increases until point b, the chemical potential of the solute 
in solution, μliquid,eq , will be equal to the chemical potential of the solute as solid phase, μsolid. 
Therefore, the solution is in equilibrium with the solid phase of one of the solutes. In this condition, 
the solution is called saturated with respect to that solid phase, and the concentration of that solid 
phase is its solubility. [13] 
The solubility of a solute is dependent on the temperature of the solution, and that 
dependency is described by the solubility curve (see Figure 2.1 and 2.2). [15] The concentrations of 
point e and f are solubility values as well. However, they are solubility’s of the same solute for 
distinct temperatures. Figure 2.2 presents a solubility curve, cs, that, like most of the systems, 
describes a system where the solubility of the solute increases when temperature increase. [14] [15] 
If the concentration of the solute further increases, point c, a solid phase starts to appear in 
the system. In this situation, the solution is said to be supersaturated with respect to the dissolved 
solute, and the chemical potential of the solute in solution, 𝜇𝑙𝑖𝑞𝑢𝑖𝑑, is now higher than the 
corresponding equilibrium value. The difference between the chemical potential of the solute in the 
supersaturated and the saturated states (see equation 2.1) is called supersaturation degree.  
 
∆𝜇 = 𝜇𝑙𝑖𝑞𝑢𝑖𝑑 − 𝜇𝑙𝑖𝑞𝑢𝑖𝑑,𝑒𝑞 = 𝜇𝑙𝑖𝑞𝑢𝑖𝑑 − 𝜇𝑠𝑜𝑙𝑖𝑑 (2.1) 
 
The supersaturation degree is a prerequisite for crystallization and it is denominated as the 
driving force of the crystallization process. [15] The degree of supersaturation at point c is related 
with the concentration difference between points b and c. [14]  
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Further increase in solute’s concentration will increase the degree of supersaturation until it 
achieves the supersaturation limit, point d. That limit is also known as metastable limit, cm. In the 
metastable region, a small amount of solute entities is formed and is stable in the solution which 
behaves like a suspension. At the metastable limit a reasonable amount of solid phase is formed and 
the crystallization spontaneously takes place. [13] [14]  
The decrease of temperature can also supersaturate a solution. For example, from points f to 
d, the decrease in temperature decreases the solubility of the solute. Therefore, new solid phase 
appears driving the solution into the metastable region. From point e to c the same phenomenon is 
verified. Nevertheless, the decrease in temperature is still not enough for the solution to achieve the 
metastable limit and spontaneously crystallize. [14] [15] 
 The crystallization phenomenon starts with the development of crystals’ nuclei, step called 
nucleation. This step is followed by further development and growth of the nuclei until the final 
crystalline structure is obtained, step called crystal growth. Nucleation and crystal growth are the two 
dominant rate processes that characterizes crystallization from solution. The manipulation of these 
mechanisms influences most of the final properties of the produced crystals, such as number, crystal 
size distribution and habit. [13] 
 
2.1.1.1. Nucleation 
Nuclei can be obtained by solute entities that spontaneously start clustering together. In this 
specific case, nucleation is called homogeneous primary nucleation. However, in practice the primary 
nucleation phenomenon is mostly heterogeneous, i.e., spontaneous nucleation occurs in the presence 
of foreign particles in solution, such as dust or dirt. Moreover, nucleation can also be promoted by 
crystals of the crystallizing compound that are already present in the solution. In that situation, 
nucleation is called secondary nucleation. [13] [15]  
 
2.1.1.2. Homogeneous Primary Nucleation  
Primary nucleation, accordingly with the Classical Nucleation Theory, starts with the 
formation of clusters. These clusters are a result of the attachment and detachment of solute entities 
in the solution. In an undersaturated or just saturated solution, the formation and decay of clusters is 
in equilibrium and the solution is stable against new phase formation. When the solution reaches a 
supersaturation state, clusters of a critical size are formed that either fall apart or became nuclei that 
grow further. [13] 
  Thermodynamically, the attention falls into the Gibbs free energy of a nucleus, ∆𝐺𝑛𝑢𝑐𝑙𝑒𝑢𝑠. 
This is characterized by two energy terms, defined in equations 2.2 and 2.3 [13], and it has to verify 
the condition described by equation 2.4 for nucleation to occur [13] [16]: 
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∆𝐺𝑛𝑢𝑐𝑙𝑒𝑢𝑠 = ∆𝐺𝑣𝑜𝑙𝑢𝑚𝑒 + ∆𝐺𝑠𝑢𝑟𝑓𝑎𝑐𝑒 (2.2) 
∆𝐺𝑛𝑢𝑐𝑙𝑒𝑢𝑠 = −
𝑘𝜐𝐿
3
𝑉𝑚
Δ𝜇 + 𝑘𝑎𝐿
2𝛾 (2.3) 
∆𝐺𝑛𝑢𝑐𝑙𝑒𝑢𝑠 < 0 (2.4) 
where 𝑘𝑣 and 𝑘𝑎 are volume and surface shape factors, 𝐿 is the characteristic length, 𝑉𝑚 is the 
molecular volume, ∆𝜇 is the chemical potential difference per solute molecule in the fluid and the 
solid, and 𝛾 is the interfacial free energy. 
The first term, ∆𝐺𝑣𝑜𝑙𝑢𝑚𝑒, defines the energy variation due to the addition of a solute entity 
into a cluster, which is negative in a supersaturated solution. The second term, ∆𝐺𝑠𝑢𝑟𝑓𝑎𝑐𝑒, defines 
the energy variation associated with the surface increment of the cluster surface. This free energy 
term is positive, since the interfacial tension between nucleus and solvent is positive. [11] [13] 
Figure 2.3 describes the behavior of the Gibbs free energy of a nucleus as the size of a cluster 
increases, assuming that a cluster has a sphere shape. As it can be seen, ∆𝐺𝑛𝑢𝑐𝑙𝑒𝑢𝑠 achieves a 
maximum value for a specific radius, 𝑟∗, which is the energy barrier that the system needs to 
overcome for nucleation to happen. For a radius below 𝑟∗, the ∆𝐺𝑛𝑢𝑐𝑙𝑒𝑢𝑠 is positive and increases 
with increasing radius. [11] [13] A positive Gibbs free energy indicates that growth of a cluster is 
unfavorable, thus the system is not stable. Therefore, the clustering of solute entities below that 
critical size tend to decay in order to reduce the Gibbs free energy. When the cluster size is equal to 
𝑟∗, the probability of adding or losing a solute entity is equal. The cluster is said to be in equilibrium 
with the supersaturated solution. As soon as the cluster has a radius superior to the critical value, the 
∆𝐺𝑛𝑢𝑐𝑙𝑒𝑢𝑠 starts decreasing. The nucleus will continue to grow since attachment of solute entities 
reduces Gibbs free energy increasing the stability of the nucleus. Therefore, the nucleation will 
proceed spontaneously. [13] [16] 
 
Figure 2.3 The Gibbs free energy, ∆𝐺 , as a function of the radius, 𝑟, of a cluster. [13] 
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The change in number of critical clusters within a certain time in a certain volume is defined 
as nucleation rate. [13] This rate is dependent on the degree of supersaturation of the system.  For a 
small supersaturation degree, the system does not have enough energy for nucleation, and thus the 
nucleation rate will be also very small, practically zero. As the supersaturation degree of the system 
increases, the nucleation rate deviates considerably from zero. From that stage on, any 
supersaturation increment will rise the nucleation rate dramatically. Moreover, it is possible to notice 
nucleation at a macroscopic level. [11] [13]  
 
2.1.1.3. Metastable limit 
As mentioned before, the metastable zone is a region where the system is supersaturated. 
However, the solid phase already formed is stable in solution without spontaneously nucleating. [11] 
[15] The boundaries of this metastable zone are the solubility curve of the system and a theoretical 
line named metastable limit (see Figure 2.2). Above this limit is the labile zone where the system is 
still supersaturated but nucleation occurs spontaneously. [15]  
The degree of supersaturation needed for spontaneous nucleation will define the width of the 
metastable zone. However, the experimental conditions and the characteristics of the system can also 
influence the metastable zone width. [11] [13] 
 
2.1.1.4. Heterogeneous Primary Nucleation 
Primary nucleation can also occur in the presence of foreign particles, which will 
spontaneously induce nucleation in their surface decreasing the associated Gibbs free energy. [11] 
The Gibbs free energy of nucleation in a surface, ∆𝐺ℎ𝑒𝑡𝑒𝑟𝑜𝑔𝑒𝑛𝑒𝑜𝑢𝑠, can be related with the Gibbs free 
energy of homogeneous nucleation, ∆𝐺ℎ𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑜𝑢𝑠, by a factor 𝜑 (see equation 2.5). Comparing the 
solute as solid phase with a droplet and assuming that the particle’s surface is flat, this factor is related 
with the wetting of the particle surface by a droplet which is characterized by the contact angle 
between the two interfaces, 𝜃. This angle indicates whether the presence of the substrate will 
substantially lower the nucleation barrier. The angle range is between 0 º and 180 º. For a 𝜃 = 180 °, 
𝜑 = 1. For this situation, the droplet will not spread on the surface because is energetically not 
favorable. Therefore, the foreign particles do not support nucleation. On the other hand, for complete 
wetting, 𝜃 = 0 °, 𝜑 = 0. In this case, the droplet spreads on the surface and there is no energy barrier 
to overcome for nucleation to occur. 
 
∆𝐺ℎ𝑒𝑡𝑒𝑟𝑜𝑔𝑒𝑛𝑒𝑜𝑢𝑠 = 𝜑∆𝐺ℎ𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑜𝑢𝑠 (2.5) 
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The factor 𝜑 is always smaller than 1. Therefore, the heterogeneous nucleation will be always more 
energetically favorable than the homogeneous one. Moreover, the nucleation rates will be higher 
even for a lower degree of supersaturation. Attention needs to be given to this energy reduction in 
order to avoid the presence of impurities in the final crystals. [11] [13]  
 
2.1.1.5. Secondary Nucleation 
 Crystals of the solute can exist in solution since the beginning of the process. Their presence 
will induce nucleation for a very low degree of supersaturation. This phenomenon is called secondary 
nucleation. There are a variety of mechanisms to promote secondary nucleation, but the most relevant 
is attrition breeding. In this method, the larger crystals collide with the impeller and the walls of the 
crystallizer and with other crystals becoming smaller crystals that act as nuclei. [13] 
 
2.1.1.6. Crystal growth 
In a supersaturated system, some solute entities will add to the nucleus produced through a 
2-dimensional molecular self-assembling promoting the growth of the nucleus into the final crystals. 
This rate process is defined as crystal growth. The mechanism of crystal growth starts with the 
migration of solute molecules from the bulk solution to the nucleus surface. These molecules are 
adsorbed and then diffuse on the surface until they find a suitable site to integrate the crystal lattice. 
[14] [17] The conditions for crystal growth are optimal when the system is at the metastable zone. 
[18] 
 
 Methods of Crystallization from solution 
Crystallization from solution can be operated in four different methods: cooling of the 
solution, evaporation of the solvent, precipitation by addition of a reactant and addition of an anti-
solvent. The initial step to select the most suitable method for a specific system is by analyzing the 
solubility curve of the system. [13] 
 
2.1.2.1. Cooling of the solution 
In cooling crystallization, the supersaturation of a solution is promoted by decreasing the 
temperature (see Figure 2.4). This decrease will reduce the solubility of the solute promoting a mass 
transfer of the solid from the solution to the solid phase. As the solubility decreases more solute 
entities are in suspension supersaturating the solution. Further decrease of the temperature will start 
nucleation thus will start the formation of crystals. [11] [13]  
Cooling crystallization is mostly applied for moderate to highly soluble solutes whose slope 
of solubility curve is positive and steep, i.e., slope usually higher than 0.005ºC-1. The feed and the 
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crystallizer temperatures are usually lying in the temperature range of the steepest region of the 
solubility curve. Therefore, a reasonable large amount of solid is obtained for a small temperature 
range. [13] 
The crystallizer temperature needs to be as low as possible to minimize the product loss. 
However, the yield of the crystallization will be restricted by the solubility of the solid at the lowest 
temperature of the process. This limitation is the main obstacle of cooling crystallization which can 
be overcome by recycling the solution upstream in the process. Otherwise the solution will be 
conducted to a second crystallization step like anti-solvent crystallization. [13] 
From an energy point of view, cooling crystallization is the best option and is a simple 
operation. In stirred crystallizers, heat exchange can occur by indirect and direct cooling. Indirect 
cooling occurs via the scrapped or non-scrapped surface of the crystallizer. For systems with intense 
scale, direct cooling is a better option which is promoted by adding an immiscible liquid or gas, 
called refrigerant, into the solution. Vacuum cooling, also known as vacuum crystallization or flash 
cooling crystallization, can also be an option for intense scaled systems. The pressure in the 
crystallizer is kept below the vapor pressure of the solution. Therefore, the solvent flashes off and 
the solution is adiabatically cooled down until the boiling temperature of the solution for the 
crystallizer’s pressure. This operation is applied, for example, in multi-stage operation and in vapor 
recompression decreasing the energy consumption. [13] 
 
2.1.2.2. Evaporative crystallization 
Evaporative crystallization is a concentration-driven method promoted by decreasing the 
quantity of the solvent. The latter will rise the concentration of the solute in the solution 
supersaturating the system (see Figure 2.4). Further removal of the solvent will promote nucleation 
initiating crystals formation. [11] 
Similarly, to cooling crystallization, evaporative crystallization is mostly used for 
moderately to highly soluble compounds. The solubility curve of the systems that undergo this 
crystallization method has a flat slope because cooling crystallization results in a low yield for those 
systems. However, evaporative crystallization can be applied regardless the solubility curve’s slope 
of the system. [13] 
The majority of the evaporative systems are operated at high temperature, above 50 ºC, and 
use low pressure steam, 4 bar, or by-product steam, 1 to 2 bar, from another chemical process. This 
crystallization method, as well as cooling crystallization, is not suitable for thermally unstable 
compounds and solid solutions. [13] 
 The energy consumption of this method is higher than the cooling crystallization. In 
continuous evaporative crystallization, in order to reduce the energy demand, multiple-effect 
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evaporation is applied. In this operation, the heat needed to vaporize the solvent in an effect is 
provided by the condensation of the solvent from a previous effect. Another option is a single effect 
evaporator with mechanical or thermal vapor recompression. These evaporators are denominated 
reduce-pressure evaporative crystallizers to distinguish them from vacuum cooling, which operates 
without an external heat source. Nevertheless, vacuum evaporation is often selected in order to take 
advantage of cooling and evaporation simultaneously. [13] 
 
 
Figure 2.4 Scheme of the cooling and evaporative crystallization through a solubility curve. [13] 
 
2.1.2.3. Precipitation [13] [14] 
 Precipitation is applied for substances whose solubility in a specific solution is very low. 
This method is mainly based in mixing two miscible reactant streams which will produce a solid 
compound sparingly soluble in the reaction mixture. If the reactant streams are highly concentrated, 
the solubility of the product will be largely exceed promoting a fast formation of the solid phase.  
[13] As a consequence of the high rate of nucleation, specifically primary nucleation, the crystals 
obtained will be small and are mostly aggregates and agglomerates. [14] 
 Precipitation promotes the deposition of impurities, such as polymorphs or amorphous 
materials, together with the product and a high agglomeration rate. In order to improve the quality 
of the solid phase, measures should be taken to reduce the supersaturation degree at the inlet of the 
crystallizer, such as decreasing the mixing time.  [13] 
 
2.1.2.4. Anti-solvent crystallization [13] 
Anti-solvent crystallization is often coupled to a cooling crystallization step to recover the 
residual amount of a high added-value product due to the resulting high yields. The method is also 
suitable for heat sensitive substances that cannot undergo an evaporative or cooling crystallization.  
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An anti-solvent is usually a liquid added to a solution in order to decrease the solubility of 
the solute in the mixture. The solubility reduction will depend on the ratio between the solvent and 
the anti-solvent abundancies. The addition of the anti-solvent also dilutes the mixture. Therefore, 
crystallization occurs if the effect of the decrease in solubility is higher than the dilution effect. For 
an aqueous solution, it is often used an organic liquid as anti-solvent. This will decrease the water 
activity decreasing the solubility of the solute in the mixture. Sometimes a highly soluble salt is added 
to the aqueous solution instead of a liquid. This method, called salting out, has the same result as the 
addition of the organic liquid. The presence of the salt decreases the water activity, thus the solubility 
of the solute decreases.  
 The solubility of the solute in this crystallization method is mostly very low which results in 
a large degree of supersaturation. As a consequence, the crystallization will be fast and the quality 
of the product will be low, similar to precipitation.  
 One of the disadvantages of this process is the need to separate the anti-solvent from the 
remaining mixture.   
Figure 2.5 helps understanding how crystallization is promoted in the last two crystallization 
methods approached, as well as exhibits their similarity. 
 
 
Figure 2.5 Scheme of precipitation and anti-solvent crystallization through a solubility curve. [13] 
 
2.1.2.5. Selection of the crystallization method [13] 
 The most suitable crystallization method for a specific system is initially chosen based on 
thermodynamic considerations, which take into account the solubility curve of the solution. 
Nevertheless, the final decision also depends on operational features of the crystallizing system, such 
as scaling and thermal stability, economical factors, such as energy consumption, among others. 
 The specifications of the final crystalline product also influence the selection of the method 
(see Table 2.1). For a highly pure crystal, melt crystallization is the most suitable method, rather than 
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crystallization from solution. If the target is large pure crystals, cooling or evaporative crystallization 
are the best option. Otherwise, for fine solids or agglomerate particles, anti-solvent crystallization 
and precipitation are the most appropriate. 
 
Table 2.1 Characteristics of the solid product obtained by melt crystallization and the different methods of 
crystallization from solution. [13] 
Crystallization 
Method 
Features of the process Product quality 
Solubility 
(wt %) 
Relative 
supersaturation, σ 
Particle size 
(μm) 
Purity 
Melting 
Crystallization 
90 0.001 to 0.01 Product is a liquid Very good 
Cooling 
Evaporative 
10 to 30 0.001 to 0.01 100 – 1000 Good 
Precipitation 
Anti-solvent 
<0.01 1 to 100 
0.5 – 100 
(agglomerates) 
Poor 
 
 Continuous crystallization. Microfluidics crystallization 
A crystallization unit is mostly integrated in downstream processing operations as a 
separation or a purification step. [15] Crystallization can be operated in two different modes, 
continuously or batch-wise.  
Batch operation is mostly applied for multi-purpose units, for processing high-value products 
due to reduced off-spec losses, and for small production capacities. Although this operation mode is 
characterized by its simplicity of equipment, it is only an economical option for capacities inferior 
to 1 m3day-1. A batch operation provides the possibility of cleaning the crystallizer after every cycle 
which allows the removal of any encrusted compound, avoiding product contamination and slow 
formation of undesirable polymorphs. [15] 
Although batch crystallizers are the most applied ones, they have limitations, such as low 
reproducibility and wide size distribution, that compromise the quality of the crystalline product. 
[12] On the other hand, continuous plug flow crystallizers allow a narrow size distribution and high 
reproducibility due to the crystallization of the solute under uniform conditions when steady state is 
achieved. Additionally, the uniform product quality obtained in this operation eliminates the need of 
downstream corrective actions adopted in batch operation. [12] [19] A continuous crystallizer also 
benefits from higher productivity and material throughput as well as better process control. The latter 
allows the control of important product characteristics, such as crystal size distribution. [12] 
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Microfluidics crystallization 
Currently, it is increasing the interest of performing continuous crystallization in a 
microfluidic system. The microfluidic technology is a tool that provides a better insight of the 
crystallization phenomenon and crystals formation as well as a better control and manipulation of 
nucleation and crystal growth. These advantages are applicable for organic, inorganic and metal-
organic solid materials. [17] [20] 
Microfluidics is a field of science that studies the behavior of fluids at sub-millimeter scale. 
The dimension of a microfluidic system is in the range of 1 to 1000 micrometer. At this scale, the 
flow regime in a micro channel is laminar, due to the small Reynolds number, often inferior to unity. 
[20] Therefore, mass transfer occurs through diffusion providing a higher control of the local 
concentrations at the two fluid streams boundary, and heat transfer occurs through conduction. 
Furthermore, the increased surface to volume ratio enhances as well mass and heat transfer which 
results as well in a better control of operating parameters like temperature and concentration. [17] 
Consequently, microfluidic crystallizers can yield crystals with a narrow size distribution.  
Microfluidic technology also simplifies the integration of analytical and detection equipment 
in the production system. Crystal formation can thus be followed during all the operation providing 
online information about the system and the rate processes of crystallization. Moreover, this 
integration increases process control.  
Although these systems are at sub-millimeter scale they can ensure a large production of 
crystals, due to the ease of numbering up micro channels. For example, recent research showed the 
ability of parallelize micro channels promoting a feasible scaling out of the microfluidic system.  [17] 
 
 Crystal Characterization 
Crystal is the name given to the solid product obtained during a crystallization phenomenon. 
A crystal is characterized by its regular appearance resulting from both short and long-range order 
of its building blocks and from the symmetry of their arrangement. [11] [21] 
The building blocks are the molecules and atoms within the crystal which are held together 
by short-range order forces known as non-covalent interactions. The smallest building block is called 
unit cell. All unit cells in a specific crystal are the same size and contain the same number of atoms 
and molecules arranged in the same way. By simple displacements in three dimensions of the unit 
cells it is built a crystal lattice (see Figure 2.6). [11] [21] 
In order to maximize the attractive interactions between atoms and molecules, and thus 
minimize the energetic state, only well-defined symmetries in the arrangement of the buildings 
blocks are possible to build a stable crystal lattice. There are only seven regular well-defined 
symmetries possible, which are defined as crystal systems (see Figure 2.7). For pharmaceutical 
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compounds, there are three common types of crystal systems: triclinic, monoclinic and orthorhombic. 
[11] [21] 
 
 
Figure 2.6 Smallest building block of a crystal, (a) unit cell, which is repeated in all three directions via 
translation forming a (b) crystal lattice. The size of the unit cell is described by the 
lattice constants a, b, and c, and the angles α, β, and γ. [11] 
 
 
Figure 2.7 The seven possible crystal systems. [21] 
 
The conditions of a crystallization will define the long-range order and the arrangement of 
the building blocks, and, consequentially, will define the properties and functionality of the solid 
product. Therefore, it is always necessary to characterize a crystal. If the solid substance will have 
application in pharmaceutical and food industry, the need of characterization is even higher due to 
their stringent quality demands. Consequently, a variety of particle characteristics has to be narrowly 
controlled in order to meet the industrial requirements. Examples of those characteristics are crystal 
size distribution, crystal habit, polymorph forms, uptake of impurities, and degree of agglomeration. 
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[11] [13] Some of these properties will be discussed in the following subchapters, as well as the 
different analysis that can be applied to control them.  
 
2.2.1. Crystal Properties 
 
 Crystal Habit  
The shape of a crystal, also called the habit, corresponds to its external appearance. The 
crystal habit can be often mistaken by morphology. The crystal habit is related with the relative width 
and length, and the number of crystal faces. The morphology of a crystal is related with the number 
of all possible combinations of crystal faces. Nevertheless, the habit of a crystal is dependent on its 
internal structure.  [21] 
The shape of a crystal can be classified as acicular (needle-like), platy (plate-like), columnar 
(like prismatic), pyramidal, tabular, equant, lamellar, among others (see Figure 2.8). [11] [21]  
 
 
Figure 2.8 Examples of some crystal habits. [21] 
 
The bioavailability of a drug does not present significant differences with distinct habits. On 
the other hand, differences in the ability to inject a suspension containing a drug in the solid phase 
are identified for distinct crystal shapes. For example, plate-like crystals are easier to inject through 
a fine needle than needle-like crystals are. The shape of a crystal also influences the downstream 
processing characteristics of the solid. For example, acicular crystals exhibit easier tendency to break 
easily, and thus cause poor filterability. Moreover, tableting can be also compromised due to the 
change in flow and compaction characteristics promoted by distinct shapes. [11] [13] [21] An 
example is the powder bridging in the hopper of the tablet machine and the capping problems during 
tableting caused by the plate-like habit of tolbutamide crystals. [21] 
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The different shapes of a crystal are a consequence of two factors, a thermodynamic factor 
and a kinetic factor. The first is related with the structure of the crystal lattice, which is influenced 
by the bond energies between the building blocks. The second is related with the crystal growth rate, 
which is affected by the solvent selected for the operation and the presence of impurities in the 
solution. [13] [21] There are impurities that are desired impurities because they were added to the 
solvent in order to modify the shape of the crystal. For example, some additives, such as surfactants, 
can modify the crystal habit by adsorbing onto growing faces during crystal growth. [11] 
[21]However, the easiest way to modify the shape of the crystal is by changing the solvent in use. 
The interactions between the solvent and the chemical structure surface of the crystal faces have an 
important role in shaping a crystal. By modeling, it is possible to know which interactions must be 
intensified, polar or apolar interactions, and thus, which group of solvents must be used to obtain the 
desired crystal habit. [11] 
 
 Crystal Size Distribution, CSD 
The crystals of a given solid powder do not possess precisely the same size. In fact, the size 
of the crystals corresponds not to a single size value but to a range of size values. This range is 
commonly called as Crystal Size Distribution, CSD, which is one of the most important tools to 
characterize the size of a solid product. CSD is mainly represented as a number distribution or a mass 
distribution, which present the total number or mass of crystals between 0 and L, respectively. These 
functions can be displayed as differential or cumulative distributions (see Figure 2.9). [11] [13] 
 
 
(a)                                                                       (b) 
Figure 2.9 Two different Crystal Size Distribution representations: (a) number distribution and (b) mass 
distribution. Q0 and Q3 are cumulative distribution functions and q0 and q3 are differential distributions also 
known as density functions. [11]    
 
 The CSD influences the performance of the product, like dissolution and bioavailability, as 
well as product quality. For example, when the final product has to be dissolved or digested, small 
crystals are needed in order to reduce the dissolution time. Therefore, the CSD of the product has to 
q
3
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Q
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follow a narrow distribution in the small diameters region. Additionally, CSD also influences the 
performance of the downstream operation, such as separation of the crystals from the mother liquor, 
and subsequent drying. In this situation, small crystals are not as suitable as previously. Their large 
surface area to mass ratio promotes a higher mother liquor adhesion after filtration, resulting in a less 
pure product after drying. CSD is also essential for storage and handling of the final product. [13] 
[22]   
 The Crystal Size Distribution of the solid compound in consideration is mainly manipulated 
by the degree of supersaturation. [11] [13] [22] Figure 2.10 shows the supersaturation dependence 
of the crystal size and of the kinetic steps of a crystallization process. 
As it can be seen, as the supersaturation increases, besides the initial rise in crystal size, the 
size of a crystal quickly decreases. For a low degree of supersaturation, the new solid phase in 
solution will adsorb faster in the surface of the crystals already in solution rather than nucleating. 
Therefore, the size of the crystals will rise. Further supersaturation of the solution will increase the 
nucleation rate until this is higher than crystal growth rate.  For this situation, the new solid phase 
will mainly nucleate leading to the production of small crystals. [11] [13] 
 
 
Figure 2.10 Qualitative diagram of the supersaturation dependence of the nucleation rate, the growth rate, 
and the crystal size, for a secondary nucleation system. [23]   
 
 The degree of supersaturation can also influence the crystal shape and the degree of 
agglomeration. For example, if the supersaturation is slowly induced, large well-formed elongated 
plates are yield. On the other hand, if supersaturation is quickly induced, fine needles that readily 
can agglomerate are synthesized. [11] [13] 
 
 Polymorphism 
A singular compound can crystallize as distinct crystal morphologies. This phenomenon is 
known as polymorphism and occurs when the molecules of a compound are arranged as different 
Chapter 2 Literature Review 
23 
 
crystal lattices (see Figure 2.7). [11] [13] [21] For simple substances, such as mineral compounds, 
which have a fixed structure, polymorphism only occurs by different packing arrangements in the 
crystal lattice. On the other hand, organic compounds have a flexible molecular structure which 
presents rotational degrees of freedom around a single bond. Therefore, polymorphism can occur, 
not only by different packing arrangements, but also by different orientation or conformation of the 
molecules at the lattice sites (see Figure 2.11). [13] [21] 
Polymorphs of a given compound are different in morphology resulting in a difference in 
free energy. Therefore, polymorphs will exhibit distinct physical and chemical properties, as well as 
distinct mechanical properties. [13] [21] This variation of the properties will strongly influence the 
processing and the end use of the compound. [13] For example, different structures present different 
Gibbs free energy of formation which represents the relative stability of the forms. The more stable 
the polymorph is, the lower is its solubility. Differences in solubility can compromise the 
bioavailability of the given compound. This fact is one of the reasons why polymorphism is 
extremely important in the Pharmaceutical industry. [11] [13] [21] Nevertheless, the variation of 
properties promoted by polymorphism is also relevant for other industries that work with solid 
compounds. For example, Food industry analyses the possible changes in taste of different forms 
while Pigment industry studies the color variation promoted by polymorphism. [11] [21] 
 
 
Figure 2.11 Polymorphs of glutamic acid: (a) orthorhombic α-form and (b) orthorhombic β-form. [13] 
 
Polymorphs present different morphologies, and thus will also exhibit different crystal habit. 
Paracetamol presents two polymorphs which exhibit distinct crystal systems, orthorhombic and 
monoclinic. The first one has needle-like habit, and the second one exhibits prism and plate habits 
(see Figure 2.12(a)). The variation of the crystal habit, as mentioned before, can be responsible for 
compromising the tableting and the injection of the substance. [13] [21] 
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(a)                                                                                (b)  
Figure 2.12 Photomicrographs showing the solution-phase polymorphic conversion of orthorhombic 
paracetamol, needle-like habit, to monoclinic paracetamol, prismatic and platy habits. Micrograph (a) was 
taken at t = 0 minutes and (b) was taken at t = 30 minutes. The scale bars are equal to 250 μm. [21] 
 
In summary, all solid-state forms of a given compound, as well as their properties, must be 
acknowledged in order to identify which polymorph offers the desired characteristics. Furthermore, 
the optimal polymorph must be analyzed to guarantee that it can be produced reproducibly and it 
does not undergo undesired conversions during its lifetime. [11] 
Figure 2.12 also shows a phenomenon that can occur in a polymorphic system. As it can be 
seen, from picture (a) to (b), orthorhombic paracetamol is transformed into the monoclinic 
paracetamol. In this particular system, this phenomenon occurred in 30 minutes. However, in other 
systems, this conversion of the less stable form to the most stable form can occur during processing 
or storage. To avoid this particular situation, the relative stability of the polymorphs has to be 
determined. [11] [13] [21] 
As mentioned before, the stability of a compound is related with its Gibbs free energy of 
formation. To study the stability of the different solid-state forms, the Gibbs free energy of formation, 
𝐺, as well as the thermodynamic state functions of entropy, 𝑆, and enthalpy, 𝐻, have to be described 
as a function of temperature, equations 2.6 – 2.8. [11] [13] 
 
𝐻 (𝑇) = 𝐻0 + ∫ 𝑐𝑃,𝑚(𝑇) 𝑑𝑇
𝑇
0
 (2.6) 
𝑆 (𝑇) = 𝑆0 + ∫
𝑐𝑃,𝑚(𝑇)
𝑇
 𝑑𝑇
𝑇
0
 (2.7) 
𝐺(𝑇) = 𝐻(𝑇) − 𝑇 ∙ 𝑆(𝑇) (2.8) 
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where 𝑇 is the absolute temperature, 𝐻0 is the enthalpy at 0 Kelvin, 𝑐𝑃,𝑚 is the molar heat capacity 
at constant pressure, and 𝑆0 is the entropy at 0 Kelvin.  
Furthermore, enthalpy and free energy equations have to be applied to the polymorphs of the 
given compound as well as to the liquid phase, melt, of the same compound in order to plot them as 
a function of temperature. Figure 2.13 shows the qualitative energy-temperature diagram of a 
polymorphic system composed by two polymorphs for two distinct situations. [11] 
As it can be seen, in both diagrams the free energy of the liquid phase, 𝐺𝑙𝑖𝑞 , intersects the 
free energy of both polymorphs, 𝐺𝐼 and  𝐺𝐼𝐼. The intersection points correspond to the melting points 
of the polymorphs, 𝑇𝑚,𝐼 and 𝑇𝑚,𝐼𝐼. The identification of the polymorphs is commonly based on their 
melting points, where the polymorph with the highest melting point is labeled as I, the polymorph 
with the second highest melting point is labeled as II, and so on. [11] [13] 
Figure 2.13(a) represents an enantiotropic system where the free energy curves 𝐺𝐼 and  𝐺𝐼𝐼 
intersect with each other before any of the polymorphs have achieved its melting point. The 
intersection point is called transition point because a conversion of the solid form is verified from 
that temperature. For a temperature below the transition temperature, 𝑇𝑡, polymorph II is the most 
thermodynamically stable form, 𝐺𝐼𝐼 < 𝐺𝐼. Above the transition temperature, 𝐺𝐼𝐼 is higher than 𝐺𝐼. 
Therefore, polymorph I is then more thermodynamically stable than polymorph II until it achieves 
its melting point. Figure 2.11(b) represents a monotropic system where an intersection between the 
free energy curves of the polymorphs is not verified before any of them achieves its melting point. 
In this system, as 𝐺𝐼 < 𝐺𝐼𝐼, the polymorph I is the most stable solid form for all temperature range 
below its melting point. [11] [13] 
 
 
Figure 2.13 Qualitative energy-temperature diagram for an enantiotropic system, (a), and a monotropic 
system, (b). The temperature regions of the stable forms are also represented. [11] 
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The identification of a polymorphic system can also be done based on the enthalpy of fusion, 
according to the Burger-Ramberger fusion rules. If the fusion enthalpy of polymorph I is lower than 
the fusion enthalpy of polymorph II, ∆H𝑚,𝐼 > ∆H𝑚,𝐼𝐼, the system is monotropic (see Figure 2.13(b)). 
If ∆H𝑚,𝐼 < ∆H𝑚,𝐼𝐼, the system is classified as enantiotropic (see Figure2.13(a)). [11] [13]  
 After discussing the thermodynamics of a polymorphic system, it is important to study the 
kinetics of the crystallization of polymorphs. As studied previously, see beginning of Chapter 2, to 
better follow the process of crystallization, the solubility curves of the compounds are needed. [11] 
[13] Figure 2.14 presents the solubility curves of the two polymorphic systems studied, monotropic 
and enantiotropic.  
 
 
Figure 2.14 Qualitative representation of the solubility curves of a monotropic and enantiotropic system. [13] 
 
As it can be seen, the behavior of the solubility curves is similar to the behavior of the free 
energy curves for both monotropic and an enantiotropic system. This is a consequence of the 
relationship between the solubility and the Gibbs free energy, where the solubility of one of the solid-
state forms of a given compound is defined as the thermodynamic state where the Gibbs free energy 
of the solid is equal to the Gibbs free energy of the solid in solution. [11] [13] 
 For an enantiotropic system, similarly to the free energy curves, the solubility curves also 
intersect with each other at the transition temperature (see Figure 2.15). This temperature is mainly 
dependent on the solid crystal lattice structure of the polymorph. The effect of changing the solvent 
will be only pronounced in the concentration as well as in the width of the metastable region. [11]  
As mentioned before, see Chapter 2.1.2, spontaneous nucleation only occurs when the 
solution is at the limit of the metastable region or beyond it. Therefore, if the metastable regions 
widths of both polymorphs are overcome during a crystallization operation, the less stable form will 
crystallize first, according to the Ostwald’s rule of stages. This rule implies that the polymorphs will 
crystallize in sequence from the less stable form to the most stable form. However, this rule was not 
verified in numerous systems but it is useful for designing polymorphs screens. [11] [13]  
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Figure 2.15 Qualitative diagram of the solubility curves of two polymorphs in an enantiotropic system and of 
the corresponding metastable region limits. 𝑇𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚 corresponds to the transition temperature. [13] 
 
During a crystallization is possible to yield more than one polymorph under similar 
conditions. This phenomenon is called concomitant polymorphism and can occur when the 
conditions of the crystallization are near the intersection of the metastability limits. [11] 
The reproducibility of the crystallization of a metastable form is quite challenging due to the 
“disappearing polymorphs”. These are polymorphs that can be synthesized at some stage but cannot 
be reproduced later. In any case, all the possible solid-state forms of a given compound must be 
identified and characterized in order to avoid serious problems related with unexpected conversion 
to a new polymorph. [11] [13] 
 
2.2.2. Characterization Methods 
 
2.2.2.1. CSD Characterization [11] 
Numerous methods are available to assess CSD. Their selection is dependent on the particle 
size range of the product in consideration and on the desired information. Examples of methods are 
Microscopy, Sieving and Laser Light Diffraction.  
Microscopy provides information about both shape and size of the crystals. However, it is a 
very superficial analysis due to the very small amount of crystals that can be analyzed, providing 
results with large statistical error. Sieving can also be applied to determine CSD. This method 
continues to be a choice for many measurements because of being simple, inexpensive and of easy 
interpretation. This technic is based on separating the crystals by sieves of different sizes, where the 
size range is larger than 20 micrometers. Nevertheless, this method can lead to crystals breakage 
compromising the crystal size distribution. 
The most applied method is laser light diffraction. This method provides a very large size 
range, excellent statistics and speed, and ease of use. The dynamic range of particle size diameters 
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goes from 0.2 to 2000 micrometers. Laser light diffraction is suitable for dry powders as well as for 
suspensions. This technic is based on the principle that particles, when illuminated by coherent light, 
will scatter light at an angle that is directly related with their size. Therefore, the size distribution is 
determined from the intensity distribution measured by the proper equipment. Frequently, the CSD 
representation obtained is a volume distribution of equivalent spherical particles. In other words, the 
result obtained is a distribution of diameters of spherical particles that interact with the laser light 
similarly as the nonspherical particles in the sample in consideration. Consequently, when comparing 
the results of this method with another CSD technic differences may be detected. 
 
2.2.2.2. Polymorphs characterization 
A given compound, as mentioned previously, can have distinct crystal structures in solid 
state, which exhibit distinct properties. This variation of characteristics can compromise the final use 
of the compound (see Section 2.2.1.3). Therefore, the presence of different structures in the solid 
powder of the compound in consideration must be verified.  
The Powder X-ray Diffraction, PXRD, is the first choice for polymorph characterization. 
This technic is based on the irradiation of a sample of crystal powder of the given compound with an 
X-ray beam. The crystal planes within the crystal lattices, when irradiated, they will give rise to a 
constructive interference at a specific angle. At the end, it will be obtained an average pattern of the 
angles detected from the crystal structure irradiated, see Figure 2.16. As different polymorphs present 
different structures, they will exhibit different PXRD patterns. [11] 
 
 
Figure 2.16 PXRD of a sample of paracetamol that exhibits two different solid-state forms. [11] 
 
The particles need to be randomly oriented in order to the crystal planes in the crystal lattice 
being suitably oriented with respect to the X-ray beam. Otherwise, some of the lines in the PXRD 
can be highly attenuated or even disappear. To avoid these errors, numerous samples should undergo 
this method or an additional analysis should be used to be compared with the PXRD information. 
[11] 
Chapter 2 Literature Review 
29 
 
Nuclear Magnetic Resonance spectroscopy, NMR, as well as Raman spectroscopy, can be 
used to provide additional information related to the existence of polymorphs. These technics, unlike 
PXRD, are sensitive to local order and local properties, i.e. chemical structure. [11] 
In Raman spectroscopy, the crystal powder sample is irradiated with a monochromatic laser 
beam. The molecules of the crystals will interact with the laser beam promoting scattered light. If the 
scattered light has a different frequency from that of the incident light, it will be used to construct a 
Raman spectrum, by either measuring the frequency or the intensity of the scattered radiation. The 
vibrations within the molecules are influenced by the environment of the molecules and the crystal 
packing. Therefore, as polymorphs have different crystal arrangements, they will have different 
spectrums, Figure 2.17. [11] [24] 
Raman spectroscopy does not require sample preparation and can be easily adapted for online 
monitoring. Additionally, this spectroscopy analysis readily reaches low frequencies, the 
characteristic range of lattice vibrations, where the differences between polymorphs is frequently 
highly pronounced. [11] 
 
 
Figure 2.17 Raman spectrum of a paracetamol sample. [11] 
  
 NMR spectroscopy is a method that takes advantage of the fact that nuclei of atoms exhibit 
magnetic properties that can be used to collect chemical information. This method gives chemical-
specific structural information and narrow well-resolved bands. However, this method requires a 
large sample, around 300 mg, and a large time window to obtain the spectrum. Additionally, it is an 
expensive method. [11] [25] 
From a practical standpoint, it is important to determine if a given system is polymorphic, 
by applying the previous methods or any other, and whether it is monotropic or enantiotropic system. 
In case of enantiotropic, it is relevant to measure the transition temperature. This information will 
provide the temperature range at which the desired polymorph is stable, assisting the design of the 
crystallization and downstream operation to avoid conversion of the solid-form during synthesis and 
storage. [11] [13] 
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 A thermal method that can be adopted to characterize the polymorph system is a Differential 
Scanning Calorimetry, DSC. One of the major DSC modes applied is called heat flux DSC. In this 
mode, the sample and the reference are heated or cooled in different compartments of the same oven 
and the temperature difference between them it is being measured as a function of temperature. From 
the temperature difference measured, it is calculated the heat flux difference between the sample and 
the reference. From this information, a thermogram is obtained where the peaks correspond to a 
phase transition. If only one peak is observed and it corresponds to a melting phenomenon, the 
melting temperature is determined accurately by applying a tangent to the melting peak and the 
correspondent enthalpy of fusion is determined by the area under the peak. [11]  
 When applied to a polymorphic system, one of three distinct DSC thermograms can be 
obtained. One of the possible thermograms can only show the melting point and melting temperature 
of the metastable polymorph. A second possibility is that the thermogram indicates that the 
metastable polymorph started to melt and was immediately followed by its recrystallization into the 
high melting temperature form, which started to melt afterwards (see Figure 2.18). The last 
possibility is that the thermogram describes a solid-solid transition from the metastable to the stable 
form followed by the melting of the last one. [11] 
 
 
Figure 2.18 DSC thermogram of carbamazepine form III: a solid–solid transition of form III to form I occurs 
at 170 ºC followed by the melting of form I at 190 ºC. [11] 
  
If from the obtained thermogram it is possible to determine the melting temperatures and the 
fusion enthalpies of the polymorphs, the system can be characterized into monotropic or 
enantiotropic by applying the Burger-Ramberger rules. Additionally, an estimate of the transition 
temperature can be determined by applying specific equations. [11] 
  Although some compounds can decompose near their melting points, DSC data provides a 
fast prediction of the relative thermodynamic relationship between the different solid-state forms of 
a given compound. [11] [13] 
 
  
Chapter 3 
MATERIALS AND METHODS 
Imagination is more important than knowledge 
Albert Einstein 
 
The aim of this chapter is to describe the experimental methods applied to address the 
problem under investigation. This chapter is divided in two parts. The first comprehends the methods 
applied to optimize the unit designed for vitamin D3 crystallization in continuous micro flow. In this 
section, the two configurations optimized are explained as well as the two different studies developed 
for one of the configurations are planned. The second part of this chapter comprehends a brief 
explanation of the technics adopted to characterize the vitamin D3 crystals produced under the 
optimization experiments. 
 
3.1. Continuous micro flow crystallization set-up  
A crystallization unit has been designed in this work to intensify the nucleation and the 
crystal growth separately. Therefore, the set-up is composed by two crystallizers. The purpose of the 
first crystallizer is to enhance nucleation while the second crystallizer aims to improve and control 
the crystal growth. The micro flow set-up built for the continuous synthesis of vitamin D3 crystals is 
shown in Figure 3.1. 
As it can be seen in Figure 3.1, the feed stream of the first crystallizer is a mixture of a solvent 
with dissolved vitamin D3 and an anti-solvent. The flow of this homogeneous mixture is manipulated 
with a valve in order to be fed as droplets. As this way, the surface to volume ratio is increased 
improving the heat transfer which optimizes the removal of the solvent. The evaporation of the 
solvent can also be verified in the first layers of the solution when it reaches the bottom of the column.  
As mentioned in Section 2.1.2, both evaporation and anti-solvent addition are concentration-
driven methods. The evaporation of the solvent, which must have a higher volatility, promotes the 
increase of vitamin D3 concentration in the anti-solvent. Furthermore, the vitamin has lower solubility 
in the anti-solvent. Therefore, the increase in concentration will quickly promote the supersaturation 
Chapter 3 Methodology 
32 
 
of the solution. Further evaporation will dramatically increase the supersaturation of the liquid 
mixture, and thus rise the nucleation rate and nucleus density. The supersaturated solution of anti-
solvent and vitamin D3 is pumped from the first to the second crystallizer, while the solvent 
evaporated is recycled into the synthesis unit. 
The glass column used for the first crystallizer is covered with a heating coil that keeps 
temperature high enough to promote the evaporation of the solvent while maintaining the anti-solvent 
in the liquid phase without isomerizing the vitamin. 
 
 
Figure 3.1 Scheme of the unit for vitamin D3 crystallization in continuous micro flow. 
 
The unit for crystal growth consist of a glass vessel designed to have an integrated cooling 
jacket that is filled with a cooling liquid. Inside the vessel is the second crystallizer which 
corresponds to a perfluoroalkoxy, PFA, tube. The vessel is also filled with the cooling liquid to 
enhance the cooling of the crystallizer.  
Flowing from a high temperature to a cooled stage, the solubility of vitamin D3 in the anti-
solvent decreases, increasing the production of solid phase. If the solution is in the metastable region, 
the solid phase formed in the crystallizer and the remaining clusters produced in the previous vessel 
will promote the growth of the nucleus into crystals.  
After the second crystallizer, a filter is integrated in the system to collect the synthesized 
crystals. The permeate stream is made of vitamin D3 dissolved in the anti-solvent and solid phase 
that did not grow enough to be retained. This stream is recycled to recover vitamin D3 and is added 
to the anti-solvent feed of the system. 
The explained process was studied in two different set-up configurations. The difference 
between both is only the equipment used to flow the supersaturated solution through the crystallizer. 
The following sections will present each configuration and the method associated to study and 
optimize the crystallization of vitamin D3. 
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3.2. Solvent and Anti-solvent selection 
The selected solvent was 2-methoxy-2-methylpropane or t-butyl methyl ether. This liquid 
was selected as a solvent for the vitamin D3 synthesis step (see Section 1.4). However, as it fulfilled 
the demands for the crystallization step, high volatility and high solubility of vitamin D3, it was also 
chosen for the third step of the project. 
Previously to the continuous crystallization study of this thesis, the crystallization of vitamin 
D3 was performed in a batch-wise operation with the objective to obtain information regarding the 
system composed by vitamin D3 and t-butyl methyl ether. Additionally, the batch crystallization was 
needed to verify if the continuous process was achievable. Through the crystallization in batch, both 
anti-solvent and operating temperatures were selected. The later will be approached in the following 
section.  
The selection of the anti-solvent was dependent on two important features. The first one was 
that the boiling point of the anti-solvent needs to be significantly higher than the solvent in order to 
allow its successful evaporation without losing any anti-solvent. The second one was that the 
solubility of vitamin D3 on the anti-solvent must be lower than the solubility of the vitamin in the 
solvent. To select the anti-solvent, a variety of liquids was tested in a batch-wise crystallization from 
which acetonitrile gave the best performance.  
Acetonitrile has a boiling point of 82 ºC [26] higher than t-butyl methyl ether, which has 55 
ºC [26]. Regarding the solubility of vitamin D3, Figure 3.2 presents the solubility curve of vitamin 
D3 in acetonitrile. As it can be seen, there are two set of curves presented in Figure 3.2. However, 
this study will use the solubility curve represented by the blue color, because this one was obtained 
in the batch study mentioned previously. 
 
3.3. Operating conditions 
The crystallization of vitamin D3 is divided in two steps. In the first step, the solvent is removed 
from the mixture. Therefore, the operating conditions, temperature and pressure, need to be adequate. 
The pressure selected was 280 mbar and the temperature was 40 ºC. These operating conditions, 
determined from the batch studies mentioned previously, allow a fast evaporation of the solvent and 
avoid any vitamin D3 isomerization. Nevertheless, some anti-solvent can be removed from the 
mixture during the evaporation. 
In the second crystallizer, the temperature needs to be reduced in order to further decrease 
vitamin solubility in acetonitrile and thus, increment the production of solid phase. The continuous 
crystallization of the vitamin D3 was performed for a set of temperatures: 10 ºC, 5 ºC and 0 ºC (see 
Appendix A). For the first temperature, no crystals were obtained in the filter. This can be a result of 
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two facts: the mesh of the filter was too small or the temperature was not low enough promoting slow 
crystal growth and/or very small particles. For the last two temperatures, 5 ºC and 0 ºC, the system 
clogged. These temperatures allowed the production of a large amount of new solid phase, which, 
due to a fast crystal growth, resulted in the precipitation of the crystals before the filter. In conclusion, 
these last temperatures where too low.  
 
 
Figure 3.2 Solubility curve of vitamin D3 in acetonitrile: red curves correspond to the work of Liang et al. 
and blue curves correspond to the batch study performed for the operation in consideration. 
 
From these results, it was noticed that the crystallizer temperature needed to be a value in 
between the temperatures tested. Therefore, the second step of the crystallization was tested as well 
at 7 ºC (see Appendix A). This was the temperature ensuring the best performance and the one 
selected for further optimization of the system.  
 
3.4. Residence time and volumetric flow rate 
The crystallization of the vitamin D3 was performed in a microscale system. This specific type 
of system is known by its small residence time in the range of seconds. Therefore, the residence time 
of the second crystallizer was set for 1 min.  
The second crystallizer consists of a PFA tube of 130 mm of length with an internal diameter 
equal to 1.55 mm. Together with the residence time, the volumetric flow of the system was 
determined by: 
𝜏 =
𝑉
𝑄𝑣
=
𝜋 (
𝑑𝑖
2 )
2
𝐿𝑡
𝑄𝑣
 
(3.1) 
where 𝜏 is the residence time, 𝑄𝑣 is the volumetric flow rate of the mixture, 𝑉 is the volume of the 
crystallizer, 𝑑𝑖 is the internal diameter of the PFA tube and 𝐿𝑡 is the length of the tube.  
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By applying the equation 3.1 the volumetric flow was rounded to 15 mL h-1 (value recognized 
by the syringe pump) for which the residence time is approximately 59 s.      
The volumetric flow rate of the first crystallizer was manipulated manually. Therefore, it was 
only determined the residence for the second crystallizer. 
 
3.5. Optimization of the vitamin D3 crystallization process 
Optimization is based on the manipulation of the operating conditions and system 
characteristics to promote higher yield and selectivity. The study presented in this thesis aims to 
improve the crystallization of vitamin D3 in continuous flow by manipulating the ratio between anti-
solvent and solvent volumes.  
 
3.5.1. Configuration 1 – Single cycle experiments 
The experiments started with the preparation of mixtures of pure vitamin D3, pure solvent and 
pure anti-solvent (see Table 3.1). 
 
Table 3.1 Quantity of each compound for different mixtures with different anti-solvent/solvent volumes 
ratios. 
 
 The concentration of vitamin D3 was kept constant at 0.22 mol L-1. This concentration value 
was stablished regarding the specifications of the synthesis step already in development. 
Additionally, from the first experiments performed, it was noticed that the maximum capacity of 
vitamin D3 in the filter was 20 mg. Therefore, the mass of vitamin D3 added to the mixtures was 
always the same and equal to 20 mg.  
The volume of anti-solvent was determined by the volume of the solvent and the ratio under 
consideration. The solvent volume was determined from: 
 
Anti-solvent/Solvent 
volumes ratio 
Vitamin D3 
Concentration 
(mol L-1) 
Vitamin D3 
Mass (mg) 
Solvent 
Volume (mL) 
Anti-solvent 
Volume (mL) 
1.5 
0.22 20 0.236 
0.355 
2 0.473 
3 0.709 
4 0.945 
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CD3 =
nD3
Vsolvent
=
mD3
Vsolvent ⋅ MD3
 (3.2) 
 
where  𝐶𝐷3 is vitamin D3 concentration, in mol L
-1, n𝐷3 is the molar quantity of vitamin D3, m𝐷3 is 
the mass of vitamin,  𝑀𝐷3 is the molar mass of vitamin D3 (equal to 384.64 g mol
-1), and 𝑉𝑠𝑜𝑙𝑣𝑒𝑛𝑡 is 
the solvent volume, in mL.  
Figure 3.3 presents the scheme of the Configuration 1 set-up built to perform the 
crystallization experiments. Each experiment started by feeding the prepared mixture to the system 
from the feed reservoir identified in Figure 3.4. From the reservoir, the mixture flows into the first 
crystallizer with the help of a valve (see Figure 3.5(a)). In this crystallizer, previously heated until 
40 ºC, as the mixture flows through the glass column, the t-butyl methyl ether evaporates and it is 
collected when it condenses. While the solvent is evaporating, the acetonitrile is becoming 
supersaturated in vitamin D3. That phenomena can be noticed at naked eye due to a change of color. 
As the quantity of t-butyl methyl ether decreases in the mixture and the acetonitrile becomes 
supersaturated, the color changes from transparent to white. Further decrease in solvent content leads 
to a more intense white color (see Figure 3.5(b)). 
 
 
Figure 3.3 Scheme of the Configuration 1 of the set-up built for the crystallization of vitamin D3. 
 
In this configuration, the acetonitrile, together with vitamin D3, flows from the first 
crystallizer towards the second crystallizer with the help of a syringe pump of 6 mL made of stainless 
steel. This pump is connected to the system at the end of the set-up where it withdraws the permeate 
stream of the filtration (see Figure 3.4). As the permeate stream has a low content of vitamin D3 when 
compared with the supersaturated mixture in the first crystallizer, its color is either slightly white or 
transparent (see Figure 3.5(b)).   
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Figure 3.4 Photo of the set-up built for the single cycle experiments: (1) feed reservoir, (2) valve, (3) first 
crystallizer, (4) second crystallizer, and (5) syringe pump. 
 
    
(a)                                                                (b) 
Figure 3.5 Crystallization set-up for single cycle experiments: (a) first crystallizer, and (b) second 
crystallizer and the syringe pump.  
 
Each experiment takes approximately 10 minutes. At the end, the filter, previously weighted, 
is left to dry at room temperature for a while and then is dried with a vacuum pump to make sure that 
any trace of acetonitrile is removed. Then, the mass of the filter is weighted to measure the quantity 
of crystals obtained, which are then collected for future analysis (see Section 3.6).  
The crystallizer is cleaned with diethyl ether. This compound is a solvent that easily dissolves 
vitamin D3, therefore, it is used to collect the precipitated vitamin. The diethyl ether is then removed 
using a rotavap so the vitamin D3 can be obtain free of solvent, and then weighted. The latter 
procedure is also performed with the permeate stream collected by the syringe pump. If there is any 
residue of mixture in the reservoir where the initial mixture is feed to the system, the reservoir is also 
1 
2 
3 
4 
5 
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cleaned with diethyl ether and it is then removed in the rotavap. At the end, it is possible to determine 
the exact quantity of vitamin D3 that was pumped into the system through global mass balance of 
vitamin D3. 
 Additionally, the absolute yield, equation 3.3, and the filter efficiency of the crystallization 
process, equation 3.4, can be calculated.  
ηD3(%) =
mfilter
mpumped
×100 (3.3) 
Filter eff. (%) =
mfilter
mfilter + mpermeate
×100 (3.4) 
 
where ηD3 is the absolute yield of the vitamin D3, mfilter is the mass of vitamin D3 collected in the 
filter, mpumped is the mass of vitamin D3 pumped into the system, Filter eff. is the filter efficiency, 
and mpermeate is the mass of vitamin D3 collected from the permeate stream.  
 For each anti-solvent/solvent volumes ratio were carried out at least three experiments. The 
values of filter efficiency and absolute yield for each ratio correspond to an average of the values 
determined in each experiment. 
 
3.5.2. Configuration 1 – Recycle experiments  
At industrial scale the permeate stream is recycled in order to recover the vitamin D3 and 
increase process yield. For the purpose of analyzing the recycling effect on the absolute crystals yield 
and on the filter efficiency, new experiments were run where the permeate stream was reintroduced 
to the system. The scheme of the of the set-up built for this purpose is presented in Figure 3.6. 
These experiments were divided in two parts. The first part, called Cycle 1, was performed 
exactly as the experiments previously described. At the end, all system was cleaned including the 
filter. The second part, called Cycle 2, was performed similarly to the first cycle, however, the initial 
mixture was prepared differently. 
The permeate stream is collected at the end of Cycle 1. Then, it is measured the volume of 
the solution, which is assumed to be the volume of acetonitrile. Considering this volume and the anti-
solvent/solvent volumes ratio under study, it is added to the permeate solution the correspondent 
mixture of t-butyl methyl ether volume with vitamin D3. The quantity of vitamin D3 added has to 
satisfy the concentration defined initially, 0.22 mol L-1, and its calculated through equation 3.2.  
The mixture prepared with the permeate of Cycle 1 is then fed to the system starting a new 
cycle, Cycle 2. When all mixture has been processed, the same procedure explained in the previous 
section was performed.  
Chapter 3 Methodology 
39 
 
 
Figure 3.6 Scheme of the Configuration 1 of the set-up built for the crystallization of vitamin D3 where the 
permeate stream is recycled. 
 
Applying a mass balance to each cycle, it is possible to determine the mass percentage of the 
vitamin D3 in the crystallizer, in the filter and in the permeate for both cycles. Furthermore, the 
absolute yield, equation 3.3, and the filter efficiency, equation 3.4, are calculated for both cycles. 
To be able to compare the results of these experiments with the single cycle results, a global 
mass balance must be done in order to include both cycles. From the total mass balance, the absolute 
yield and the filter efficiency are determined: 
 
ηD3(%) =
mfilter,1 + mfilter,2
mpumped,t
×100 (3.5) 
𝐹𝑖𝑙𝑡𝑒𝑟 𝑒𝑓𝑓. (%) =
mfilter,1 + mfilter,2
mfilter,1 + mfilter,2 + mpermeate,2
×100 (3.6) 
 
where, mfilter,1 and mfilter,2 are the masses of vitamin D3 collected in the filter during Cycle 1 and 
Cycle 2, respectively, mpumped,t is the total mass of vitamin D3 pumped in both cycles, and 
mpermeate,2 is the mass of vitamin D3 collected in the permeate stream of Cycle 2. 
 
3.5.3. Configuration 2 – Single cycle 
During an experiment, the syringe pump cannot guarantee a continuous flow and keep 
constant the volumetric flow rate. As the filter gets filled with crystals the flow of the acetonitrile-
vitamin D3 mixture starts to reduce compromising the performance of the crystallization.  In order to 
improve the reproducibility of the experiments, a new configuration was used. Instead of using a 
Chapter 3 Methodology 
40 
 
syringe pump to circulate the effluent of the first crystallizer, micro peristaltic pumps were used 
being connected between both crystallizers, as shown in Figure 3.7.  
 
 
Figure 3.7 Scheme of the Configuration 2 of the set-up built for the crystallization of vitamin D3. 
 
 The experiments performed in this set-up were equal to the ones described for the single 
cycle experiments. 
 
3.6. Characterization of vitamin D3 crystals 
One of the goals of this project is to produce vitamin D3 crystals that can be used in dietary 
supplements. To achieve this goal, the crystals obtained must meet the requirements of the 
pharmaceutical and food industry concerning those applications. [27] The requirements are related 
with intrinsic properties, particle shape and size, and mechanical properties (see Section 2.2.1). 
Therefore, the solid product synthesized needs to be characterized to verify if the crystals satisfy such 
demands. If the properties analyzed are far from the pharmaceutical requirements, further study of 
the crystallization process is required in order to obtain the desired crystal’s characteristics.  
In this thesis, the characterization of the vitamin D3 crystals consisted in studying the Crystal 
Size Distribution, the crystals habit and the existence of polymorph forms. The crystal habit will be 
studied by optical microscope and scanning electron microscope, SEM, pictures, the CSD will be 
obtained by performing a Laser Light Diffraction, and the existence of polymorphs will be studied 
through PXRD.  
  
Chapter 4 
RESULTS AND DISCUSSION 
You cannot teach a man anything; you can only help him discover it in himself. 
Galileo 
 
This chapter is divided in two parts. The first part presents the results and discussion of the 
optimization of vitamin D3 crystallization. Then the experimental characterization of the obtained 
vitamin crystals is focused.    
 
4.1.  Optimization of the vitamin D3 crystallization process 
As mentioned in Chapter 3, two set-up configurations were developed to address the 
optimization of the continuous crystallization of vitamin D3. In the case of Configuration 1, two 
different studies were performed to demonstrate the yield and filter efficiency improvement achieved 
by recycling the permeate stream. For Configuration 2, this study was not accomplished due to 
equipment limitations as explained latter in this chapter.    
 
4.1.1 Configuration 1 – Single cycle experiments 
The crystallization was performed for different anti-solvent/solvent volumes ratios. The 
results shown in Table 4.1 were obtained applying the method described in Section 3.5, namely, the 
mass percentage of vitamin D3 obtained in different locations of the system after crystallization, as 
well as crystals yield and filter efficiency. As it can be seen in Table 4.1, the mass balance for the 
different ratios never achieves 100% due to losses of vitamin D3 in the tubing previously to the 
second crystallizer. 
The same points are plotted in Figure 4.1 for better analyzing the behavior of the process 
characteristics with increasing anti-solvent/solvent volumes ratio. As it can be seen, as the proportion 
of acetonitrile increases, the crystals yield achieves a maximum value. This behavior, distinct from 
the trend of the remaining parameters, is related with the decrease of supersaturation degree with the 
increase of the volume ratio.  
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Initially, the concentration of vitamin D3 in the anti-solvent rises as the solvent is removed 
in the first crystallization stage. For a volumes ratio of 1.5, the acetonitrile will quickly become 
saturated in vitamin D3. This fact, together with the low solubility of vitamin D3 in the acetonitrile, 
dramatically increases the supersaturation. Consequently, the nucleation rate rises, as well as the 
nucleus density, driving the solution most probably beyond the metastable limit. In the second 
crystallizer, the decrease of temperature further reduces vitamin D3 solubility in acetonitrile 
promoting the production of more solid phase. As a result, the supersaturation further increases, as 
well as the nucleation rate. When high nucleation rate is achieved, precipitation can occur. As it can 
be seen in Figure 4.1, for a volumes ratio of 1.5 most of the vitamin D3 precipitates in the second 
crystallizer, 59 %, while only 25 % is obtained in the filter.  
 
Table 4.1 Mass percentage of Vitamin D3 obtained from a total amount of 20 mg. 
 Mass Balance (%)    
Anti-solvent/ 
/Solvent Ratio 
Permeate Filter 
2nd 
Crystallizer 
Precipitate 
 
Absolute yield 
(%) 
Filter efficiency 
(%) 
1.5 3 25 59 25 89 
2 22 31 45 31 58 
3 34 52 12 52 60 
4 47 24 7 24 34 
 
 
Figure 4.1 Mass percentage of vitamin D3 obtained from a constant 0.22 mol L-1 concentration in t-butyl 
methyl ether. The experiments were performed in the 2nd crystallizer at a temperature of 7 ºC and 59 s of 
residence time. 
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As the anti-solvent/solvent volumes ratio increases, acetonitrile dissolves more vitamin D3. 
Therefore, the degree of supersaturation achieved in the first stage of the crystallization decreases, 
which slows down the nucleation. Consequently, less vitamin D3 is lost as a precipitate in the 
crystallizer and more vitamin is collected in the filter as larger crystals. This behavior can be verified 
in the results obtained (see Figure 4.1). However, for a volumes ratio of 2, the mass percentage of 
precipitated vitamin D3 (45 %) is still higher than the one filtered (31 %). As the supersaturation 
degree decreases, recalling the phase diagram for crystallization from solution (see Chapter 2.1.1), 
the solution gets closer to the metastable limit. For the situation under consideration, the solution is 
probably still beyond the metastable region, which explains why precipitation is still important.  
For a volumes ratio of 3, a maximum yield of 52 % is reached. This implies that the solution 
achieves a state where further decrease of the supersaturation degree diminishes the synthesis of 
crystals while a further increase enables crystals production as well as precipitation. Such state 
corresponds to the metastable limit. As the crystals yield is higher than the mass of precipitated 
vitamin, and a further increment of the volumes ratio decreases the mass of filtered vitamin D3, this 
may indicate that the solution achieved its metastable limit.  
Further increase of the anti-solvent/solvent volumes ratio decreases the amount of filtered 
vitamin. As mentioned previously, below the metastable limit the nucleation is not spontaneous, and 
thus the amount of obtained crystals starts to fall. Although the degree of supersaturation is high 
enough to produce new solid phase, not all solid clusters possess enough energy to generate nucleuses 
and grow further. Additionally, a higher ratio implies also higher volume of anti-solvent, which can 
dissolve more vitamin D3 as explained below. As it can be seen, for a volumes ratio of 4 most of the 
vitamin is obtained in the permeate stream and the amount of crystals produced drops. It is known 
that vitamin D3 has low solubility in acetonitrile but there is still a mass of vitamin that dissolves in 
it. For instance, at 7 ºC vitamin D3 solubility is 7.2 mg mL-1 (see Appendix B). Therefore, one may 
estimate the amount of vitamin that is expected to be lost dissolved in the permeate stream. If that 
amount is excluded from the mass balance (see Appendix B), the absolute yield of the process jumps 
from 52 % to 70 % as shown in Figure 4.2.  
In 2012, Zhang et. al developed a two-stage mixed-suspension mixed-product removal 
(MSMPR) continuous anti-solvent and cooling crystallization for a pharmaceutical intermediate. 
[28] Two different configurations were studied: the first one, Configuration A, starts with cooling 
crystallization and follows with simultaneous cooling crystallization and anti-solvent addition; the 
second one, Configuration B, starts with both cooling and anti-solvent crystallization, and in a second 
stage further cooling is performed. This crystallization is similar to the one presented in this thesis 
concerning the crystallization from solution methods applied to induce supersaturation. Nonetheless, 
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they are applied differently, and the continuous crystallization was not performed at microscale level, 
which influences the results. Nevertheless, Zang et. al crystallization experiments yield 92 % of the 
compound with purity greater than 98 %. [28] 
 
Figure 4.2 Yield of crystallization taking or not into account the solubility of vitamin D3 in acetonitrile (7.3 
mg mL-1 at 7 ºC). 
 
When comparing our results (yield of 70 %) with those of Zang et. Al (92 %), there is a 
significant difference and space for improvement. A possibility for increasing the absolute yield is 
to recycle the permeate stream in order to recover the vitamin D3 in solution that can still be 
crystallized.  
 Concerning the filter efficiency, Figure 4.1 shows that the efficiency decreases by increasing 
the anti-solvent/solvent volumes ratio. The filter efficiency, defined by equation 3.4, is the quotient 
between the mass of vitamin D3 crystals collected in the filter and the total mass of vitamin feed to 
the filter unit. When the volume ratio varies from 1.5 to 2, there is a significant increase in the mass 
quantity of vitamin D3 in the permeate (see Figure 4.1) which promotes a decrease in the filter 
efficiency. For a volumes ratio of 4, the permeate has a higher amount of vitamin than the filter, and 
thus the efficiency decreases significantly. The decrease of filter efficiency is a result of the increase 
in acetonitrile volume, which increases the amount of vitamin dissolved in the solution. Nevertheless, 
developed crystals can also be present in the permeate stream which could be too small to be retained 
in the filter. Therefore, filter efficiency could be improved by reducing the mesh of the filter to 
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increase vitamin D3 crystals collection. Nonetheless, it must be taken into account the possible 
increase in back pressure. 
 In summary, the best crystallization performance was obtained for an anti-solvent/solvent 
volume ratio of 3 that yields 52 % of crystals (see Figure 4.2) with only 12 % of loses as precipitated.    
 
4.1.2  Configuration 1 – Recycle experiments 
As mentioned above, the Recycle experiments were performed to analyze the improvement 
in crystals yield and filter efficiency when compared with single cycle experiments. 
Applying the procedure described in Section 3.5.2, the mass percentage of vitamin D3 was 
determined and compiled in Table 4.2. 
 
Table 4.2 Mass percentage of Vitamin D3 obtained from a total amount of 75 mg (0.22 mol L-1 in t-butyl 
methyl ether, solvent). 
   Mass of Vitamin D3 (%) 
Anti-solvent/ 
/Solvent Ratio 
Essay 
2nd 
Crystallizer 
Precipitate 
Filter Permeate 
3 
Recycle 
experiment 1 
Cycle 1 9 13 78 
Cycle 2 28 6 46 
Recycle 
experiment 2 
Cycle 1 14 27 59 
Cycle 2 24 15 56 
 
The results for the Cycle 1 were expected to be similar to those obtained during the Single 
cycle experiments for the same volumes ratio (ratio of 3). Recalling the results of Single cycle 
experiments, the mass percentage of vitamin D3 were 12 % in the crystallizer, 52 % in the filter and 
34 % in the permeate. As it can be seen, during the Recycle experiments most of the vitamin D3 was 
obtained in the permeate stream instead of in the filter as expected. This difference indicates that the 
residence time in the first crystallizer was not enough. The nucleation enhancement in the first 
crystallizer is denominated as primary nucleation and its rate is known to be slow for low 
supersaturation. Therefore, a short residence time does not allow the generation of a high amount of 
nucleus. When the solution enters in the second crystallizer, due to the small amount of nucleus, most 
of the vitamin D3 will remain in solution and the amount of crystals obtained will be really small.   
Recycling the permeate stream increases the quantity of vitamin D3 at the inlet of the first 
crystallizer. The high concentration of vitamin D3 promotes a faster supersaturation of the solution 
vitamin D3-acetonitrile as the solvent is removed. A high supersaturation results in high nucleation 
rate, rising the nucleus density in solution. As the solution flows through the second crystallizer the 
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temperature reduction will promote the separation of vitamin D3 as crystals. The crystals that do not 
precipitate will be collected in the filter. Therefore, from the Cycle 2 it is expected that most of the 
vitamin D3 is obtained as a precipitate in the second crystallizer and as crystals in the filter. As it can 
be seen, the quantity of vitamin D3 in the second crystallizer increases from Cycle 1 to Cycle 2 and 
the quantity of the vitamin in the permeate decreases. However, vitamin D3 is mostly found in the 
permeate stream and it was expected to be mostly found precipitated in the system. A possible cause 
for this behavior is the same as for Cycle 1, i.e. the residence time in the first crystallizer was not 
long enough. 
 The crystals yield and the filter efficiency of each cycle for the Recycle experiments are 
presented in Table 4.3. As analyzed above, the amount of vitamin D3 in the filter was reduced and 
the vitamin D3 present in the permeate stream was higher than expected in both cycles. Consequently, 
the filter efficiency from each cycle is small as well as the absolute crystals yield.  
 
Table 4.3 Absolute crystallization yield and filter efficiency of each cycle for the Recycle experiments. 
   Mass of Vitamin D3 (%) 
Anti-solvent/ 
/Solvent Ratio 
Essay 
Absolute yield 
(%) 
Filter efficiency 
(%) 
3 
Recycle 
experiment 1 
Cycle 1 13 14 
Cycle 2 6 12 
Recycle 
experiment 2 
Cycle 1 27 31 
Cycle 2 15 21 
 
After performing a mass balance for each Recycle experiment, it was determined the absolute 
yield and filter efficiency of the complete experiment. Comparing these values with those for Single 
cycle experiments – see Table 4.4 – on may conclude that a unique cycle is better than recycling the 
permeate stream.  
 
Table 4.4 Comparison of absolute yield and filter efficiency between Single cycle experiments and Recycle 
experiments. 
Anti-solvent/Solvent 
Ratio 
Experiment 
Absolute yield 
(%) 
Filter efficiency 
(%) 
3 
Single cycle 52 60 
Recycle 1 14 26 
Recycle 2 28 41 
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Nonetheless, a priori, recycling the permeate stream should increase both yield and 
efficiency, being expected to obtain better results than with a single cycle. The amount of 
experiments performed was not enough to take a strong conclusion about recycling permeate stream. 
More experiments must be carried out for a better perception of the behavior of both crystal yield 
and filter efficiency with recycling. Nevertheless, this experiments exhibit the poor reproducibility 
of this crystallization process. A possibility of improvement can be improving the pumping system 
of the configuration under study. 
 
4.1.3 Configuration 2 – Single cycle experiments 
Initially, one micro peristaltic pump was not enough to flow the solution through the filter. 
Two pumps were also not enough to overcome the backpressure created by the filter. There were 
only two pump’s controllers available. Therefore, using more pumps was not an option. The only 
options were either connect two filters in parallel or using a filter with higher surface area. Due to 
money and time limitations the second option was adopted. The increase of surface area helped 
decrease the backpressure. Consequently, the pumps had enough energy to flow the mixture through 
the filter. 
 After optimizing the set-up, the settings of the peristaltic pump, amplitude and frequency, 
needed to be tested to verify which pair of settings corresponds to the desired volumetric flow rate. 
However, for any pair of settings the flow rate was always equal to 1 mL min-1. After discussing this 
situation with the supplier, it was understood that, in order to be able to use the pumps properly, the 
system needed to be filled first with the solution. To fill the system, a syringe pump should be added 
to this configuration. At the end, the configuration would start as the previous configurations to 
further evolve into a new one, which would not be practical. Therefore, at the end, it was decided not 
to study this configuration. 
 
4.2. Characterization of vitamin D3 crystals 
As has been mentioned above, the crystal habit, crystal size distribution, and polymorphism 
are the main crystal properties under analysis in this project. The crystals of vitamin D3 produced 
during the Single cycle experiments for a volume ratio of 3 were collected in order to analyze their 
quality. Only these crystals have been analyzed because they correspond to the solid produced under 
the best crystallization performance. 
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4.2.1. Crystal Habit  
 In order to identify the crystals habit of the produced vitamin D3, both optical microscopy 
and scanning electron microscopy pictures were taken – see Figures 4.3 and 4.4, respectively.  
Figure 4.3 shows crystals exhibiting a prismatic habit. However, in Figure 4.4(a) some 
crystals, among the prismatic ones, possess a very small width, similar to needle-like crystals. Hence 
it is not clear the real habit of vitamin D3 crystals.  
 
 
Figure 4.3 Optical microscopy picture of vitamin D3 crystals obtained from experiments with anti-
solvent/solvent volumes ratio of 3. 
 
  
   
Figure 4.4 SEM pictures of a sample of vitamin D3 crystals obtained from experiments using anti-
solvent/solvent volumes ratio of 3. (a) 20 μm scale, (b) 10 μm scale, and (c) and (d) 5μm scale. 
a b 
c d 
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However, as the scale of the SEM pictures of Figure 4.4 diminishes, it becomes more clear 
that the crystals shape is prismatic. Both needle-like and prismatic crystals grow essentially in length, 
but the prismatic ones are thicker than the needle-like crystals, and the edges are round rather than 
needle-like. Such different habits can be sometimes easily confused.  
It was mentioned in Section 2.4 the disadvantages of some crystals habit. For example, 
crystals with needle-like habit are unsuitable for downstream operations, and platy-like crystals will 
impair tableting process. No disadvantages were found concerning prismatic habit. However, needle-
like and prismatic habits are close and may present a similar poor hydrodynamic behavior. 
Nevertheless, in principle, the prismatic crystals may be suitable for the various steps after 
crystallization operation until their final application. 
Besides the shape of the crystals, Figures 4.3 and 4.4 also reveal a high degree of 
agglomeration between the crystals, which occurs when particles collide and the attractive forces 
between them are superior than the repulsive forces. Agglomeration is not a desire crystal 
characteristic due to the mother liquor that is contained within the primary crystals of the 
agglomerate. That mother liquor is difficult to separate during drying, and promotes caking of the 
product during storage. Additionally, agglomerates break more easily than solid crystals, and release 
solvent during their breakage. [11] 
During crystallization, the occurrence of agglomeration depends on the degree of 
supersaturation of the solution. The higher is the supersaturation degree, the higher is the probability 
for agglomeration and the stronger is the binding between agglomerated particles. In order to reduce 
the agglomeration observed in the previous pictures, the crystallization experiments must run under 
low degree of supersaturation. Considering the results obtained for the optimization of the 
crystallization process, when the anti-solvent/solvent volumes ratio increases, the supersaturation 
level decreases. Nevertheless, the yield suffers a large reduction as well. For example, from a volume 
ratio of 3 to 4, the absolute yield decreases from 52 % to 24 %.   
 The degree of supersaturation can be also attenuated reducing the temperature difference 
between the two crystallizers. For instance, if the second crystallizer operates at room temperature, 
the decrease of vitamin D3 solubility in acetonitrile is lower, when compared with the solubility at 7 
ºC, which results in lower amounts of new solid phase. Consequently, the degree of supersaturation 
decreases. Nonetheless, the yield will also decrease since at higher temperatures the solubility of 
vitamin is also higher, promoting more loses of vitamin dissolved in the anti-solvent.   
 Reducing the residence time (i.e. incrementing the volumetric flow rate) could also hinder 
crystals agglomeration because it would provide less time for the particles to grow, thus reducing the 
probability of agglomeration in the second crystallizer. However, high volumetric flow rates can 
promote crystals precipitation, clogging the system. 
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 In summary, experiments for 3 and 4 volumes ratios may be performed under shorter 
residence times and/or higher operating temperature in order to disclose the effect on agglomeration. 
Additionally, the characterization of crystals produced during Recycle experiments should also be 
accomplished to verify if this mode of operation has any effect on both crystal habit and 
agglomeration. 
 
4.2.2. Crystal Size Distribution 
Figure 4.5 reveals crystals with a substantial size distribution. To better analyze the size of 
the crystals, a laser light diffraction method was applied to a sample of vitamin D3 in order to obtain 
the crystal size distribution, CSD. Figure 4.5 presents the obtained CSD, displayed as a density 
function, where the mean particle size value is equal to 15.03 ± 0.31 μm. As it can be seen, the size 
distribution is substantially wide. The extent of particle sizes goes from approximately 0.25 μm to 
almost 500 μm which is not desired. 
 
 
Figure 4.5 Density function obtained from laser light diffraction of the vitamin D3 crystals produced during a 
3 volumes ratio experiment.  
 
 The desired result would be a narrow distribution of small particle sizes. The smaller the 
size, the better the performance of the crystals from a bioavailability point of view. Additionally, if 
the crystals are too large, like 500 μm, the crystallizer will be clogged due to its small internal 
diameter, 1.55 mm.  
To produce small crystals, both nucleation and crystal growth rates must be high, which 
means the degree of supersaturation should be high. As mentioned before in this chapter, at a volumes 
ratio of 3, the supersaturation is high as desired for small crystals production, but the obtained CSD 
indicates the presence of large crystals in the final product. This problem may be solved increasing 
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the volumetric flow rate of the feed (i.e. reducing the residence time), and/or increasing the 
temperature in the second crystallizer to increase solubility. Attention must be paid to the increase 
of the temperature of the second crystallizer since, as highlighted before, the vitamin solubility in the 
anti-solvent increases, and the global yield is unfortunately penalized. 
In summary, experiments for a volume ratio of 3 can be performed under shorter residence 
time and/or higher operating temperature in order to obtain narrower crystal size distribution and 
smaller crystals.  
 
4.2.3. Polymorphism  
Vitamin D3 was known to exhibit only one solid form (form A), whose crystal structure is 
composed by two different conformers, α and β. In 2016 Wang and coworkers were investigating if 
the α conformer was responsible for the characteristic chemical instability of vitamin D3, and found 
that this vitamin possesses a second solid form (form B). Figure 4.6 presents the PXRD patterns of 
both forms A and B. [29] 
 
 
Figure 4.6 PXRD patterns of the two solid forms of vitamin D3 characterized by Wang and his coworkers. 
[29]   
 
After the 3 volumes ratio experiments were finished, a sample of these crystals was collected 
for PXRD analysis. Additionally, a sample of commercial vitamin D3 purchased from VWR, the 
same one used for the initial mixtures, was also inspected for comparison, as shown in Figure 4.7.    
When the patterns shown in Figures 4.7 and 4.6 are compared, it can be verified that the 
crystals synthesized in this work correspond to form B while the commercial sample corresponds to 
form A.  
Besides identifying the polymorph form of the crystals, it is also necessary to study the 
relative thermodynamic stability of the different solids to identify the most stable form. To compare 
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the stability of both forms, a DSC essay was carried by Wang and coworkers, being possible to 
identify monotropic or enantiotropic polymorphs. The form A has a melting point of 84 ºC while 
form B equals 63 ºC. Considering these melting points and the fusion enthalpies also determined by 
the DSC analysis, the energy-temperature diagram Figure 4.8 was built. [29] 
 
 
Figure 4.7 Powder X-ray diffraction pattern of (1) vitamin D3 crystals synthesized during experiments for a 
volumes ratio of 3 and (2) a commercial sample of vitamin D3 purchased from VWR. 
 
 
Figure 4.8 Energy-temperature diagram obtained for the two solid forms of Vitamin D3, form A and form B. 
[29] 
 
As can be seen from Figure 4.8, the relative thermodynamic behavior of vitamin D3 solid-
state forms correspond to a monotropic system, where form B is the less stable one. Therefore, its 
synthesis must be avoided in order to prevent conversion of form B into form A. 
 Wang et al. obtained the solid-state form B from a supersaturated acetonitrile solution at 5 
ºC, where prism-like highly crystalline form B was obtained together with form A. Further study has 
revealed that pure form B can be synthesized using alcohols as solvent and performing the 
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crystallization at -20 ºC. Wang et al. concluded that polar solvents and lower temperatures were 
advantageous for synthesizing form B. [29] Therefore, two alternatives are available to prevent the 
form B synthesis by the crystallization process of this study. Wang et al. obtained form B using 
acetonitrile, the anti-solvent selected for the crystallization in study. Therefore, an alternative can be 
changing the anti-solvent for another organic liquid where vitamin D3 has lower solubility. A second 
alternative is increasing the temperature of the second crystallizer. Wang et al. obtained form B at 5 
ºC. The crystallization in study was performed at 7 ºC, a temperature still close to the operation 
developed by Wang et al., hence the crystallization could be, for example, performed at room 
temperature. Nevertheless, it is important to remember that at 10 ºC the crystals were not retained in 
the filter (see Section 3.3). However, it was not concluded if crystals were produced or not, it only 
indicates that crystals were not large enough to be retained in the filter. Therefore, if experiments 
were performed at room temperature (ca. 19 ºC), a smaller filter mesh, 2 μm or 0.5 μm, must be used 
to guarantee vitamin D3 crystals collection. 
 In summary, the crystals produced by the crystallization process of this thesis, unlike the 
vitamin D3 obtained from VWR, correspond to the less stable solid-state form of vitamin D3, form 
B. This form can be converted into the most stable one, form A, by manipulating the temperature of 
the second crystallizer or by changing the anti-solvent.    
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Chapter 5  
CONCLUSION AND FURTHER 
RESEARCH 
 
If you believe in yourself first, you’re unstoppable 
Mendell Grinter 
 
 This chapter contains the main conclusions of the study accomplished to optimize a 
continuous micro flow unit for crystallization of vitamin D3. Moreover, some different approaches 
are presented with the objective to improve vitamin D3 crystallization at a sub-millimeter scale. 
 
5.1. Conclusions 
In this project a two-stage crystallization unit was proposed and optimized in order to 
produce crystals of vitamin D3 under continuous operation. This is a novel crystallization process 
and has been implemented under microfluid conditions to take advantage of the better control and 
manipulation of the kinetics of crystallization, as well as enhance mass and heat transfer due to the 
inherent high surface to volume ratio. In the first stage of the unit, a simultaneous solvent evaporation 
and anti-solvent addition are performed to enhance nucleation, while in the second stage the crystal 
growth is enhanced by cooling. 
Two configurations of the unit were considered to verify if reproducibility of the 
crystallization process could be improved. In Configuration 1 the supersaturated solution was 
pumped by a syringe pump, while in Configuration 2 the solution was pumped using a micro-
peristaltic pump. The later presented some equipment limitations, which solution was not practical 
for the design in study (see Section 4.1.3). Therefore, only Configuration 1 was studied. 
The optimization of the crystallization of vitamin D3 was accomplished by studying the 
influence of the ratio between the anti-solvent (acetonitrile) and the solvent (t-butyl methyl ether) 
volumes on the separation. From the four ratios studied, the volumes ratio of 3 achieved the best 
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absolute yield (52 %), for which the filter efficiency was 60 %. As there was 48 % for improvement, 
and since 34 % of vitamin was lost in the permeate stream, additional experiments were carried out 
recycling this stream to increase global yield and filter efficiency. However, the results were not 
conclusive, which implies that more essays are required for a decisive investigation.  
The vitamin D3 crystals produced under the best operating conditions were characterized in 
order to verify if they meet the pharmaceutical industry requirements. Accordingly, crystal habit, 
crystal size distribution, and the existence of polymorphs were subsequently focused. The vitamin 
crystals possess a prismatic habit, as well as a high degree of agglomeration. The crystal size 
distribution measured by laser light diffraction was significantly wide, from ca. 0.25 to 500 μm. 
Concerning polymorphism, vitamin D3 had two solid-state forms, named A and B. Form B is the less 
stable, but it was the form obtained by the crystallization process under analysis. In the whole, these 
results/characteristics demonstrate that the produced vitamin D3 crystals are not yet suitable for 
pharmaceutical application. Nevertheless, there is still room for improvements, mainly if one takes 
into account this was an exploratory research. On may cite, for example, the reduction of the 
residence time of the supersaturated solution in the crystallizers, or the increment of the temperature 
of the second crystallization stage. One should also consider the possibility to substitute the anti-
solvent (acetonitrile) for another organic liquid. 
 
5.2. Suggestions of future work 
Since the crystallization of vitamin D3 was already performed at micro scale, it could be 
assisted by segmented flow. Accordingly, an immiscible fluid is inserted in the main stream with the 
objective to segment that stream.  
In 2015, a variety of studies were published presenting improvements based on 
crystallization by segmented flow. Due to the small diameter of the micro scale crystallizers, the 
probability of sedimentation and further clogging of the flow is quite high. Applying segmented flow, 
this particular situation is avoided because the transport of all crystals is ensured eliminating the 
production of precipitates during the process. [30] Additionally, uniform sized crystals were 
observed within each slug. This was as a consequence of the recirculation, where the slurry in each 
slug is well mixed even in the absence of any static mixer. [30] [31] [32]. 
As has been mentioned in the conclusions section, several approaches can be analyzed in 
detail, namely, the influence of feed flow rate (i.e., mean residence time), temperature of cooling 
crystallization, and nature of anti-solvent upon the final yield, filter efficiency and vitamin D3 crystal 
features. Additionally, further research must be done to significantly improve the reproducibility of 
this process. 
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Appendix A Operational temperature of 
second crystallization stage  
 
The second crystallizer is the second step of the designed unit, which is based on the principle 
of cooling crystallization (see Section 3.1). The most suitable temperature of this second step should 
be determined before the optimization of the process (see Section 3.5). Therefore, the continuous 
crystallization of vitamin D3 was performed for the following set of temperatures: 10, 7, 5 and 0 ºC, 
whose results are listed in Table A.1.  
 
Table A.1 Results obtained for the two-stage continuous crystallization performed under the following 
conditions: temperature of the first crystallizer, 40 ºC; mean residence time in the second crystallizer, 59 s; 
volumetric flow rate,15 mL h-1; mesh of the filter, 10 μm; configuration of the process, Configuration 1.   
  Results* 
Temperature of the 
2nd crystallizer 
(ºC) 
Volume Ratio 
(Anti-
solvent/Solvent) 
Clogging 
Crystals present in 
the Filter 
10 1.5 YES NO 
10 3 YES NO 
0 3 YES NO 
5 3 YES YES 
7 3 NO YES 
7 3 NO NO 
7 2 NO YES 
7 1.5 YES YES 
 *Red color represents an undesired result and green color represents a desired result. 
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Appendix B Configuration 1 – Single cycle 
experiments 
 
 Vitamin D3 can appear in the permeate stream of the filtration dissolved in solution or as 
small crystals that were not retained in the filter. The mass of the vitamin dissolved in the permeate 
stream can be determined by its solubility at 7 ºC. The later can be calculated by applying the equation 
of the solubility curve shown in Figure 3.2: 
𝑦 = 0.0016𝑥2 + 0.4911𝑥 + 15.266 (B.1) 
where y corresponds to the vitamin D3 concentration, in mmol L-1, and x corresponds to the 
temperature, in ºC.  
 At 7 ºC the concentration obtained is equal to 18.782 mmol L-1. When converting for the unit 
mg mL-1, the solubility of the vitamin D3 at 7ºC is 7.2 mg mL-1. 
If the mass of dissolved vitamin D3 in the permeate stream is deducted from the feed, it can 
be observed a substantial increase of the absolute yield of the process (see Table B.1).  
 
Table B.1 Absolute yield of crystallization calculated by excluding the amount of vitamin D3 dissolved in the 
permeate stream (i.e., acetonitrile solution). 
Volumes ratio 
(Anti-
solvent/Solvent) 
Anti-
solvent 
volume 
(mL) 
Feed of 
vitamin 
D3 
(mg) 
Mass of 
vitamin D3 
dissolved in 
the anti-
solvent 
(mg) 
Maximum 
mass of 
Vitamin D3 
that can 
crystallize  
(mg) 
Absolute 
yield 
(%) 
“Corrected” 
Absolute 
yield  
(%) 
1.5 0.355 25 2.6 22.4 25 28 
2 0.473 20 3.4 16.6 31 37 
3 0.709 20 5.1 14.9 52 70 
4 0.945 20 6.8 13.2 24 36 
 
The “corrected” absolute yield can be determined by the following equations. 
𝑚𝑚𝑎𝑥 = 𝑚𝑓𝑒𝑒𝑑 − 𝑉𝐴𝑆×𝑆D3 (B.2) 
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ηD3,𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑(%) =
(𝑚𝑓𝑒𝑒𝑑×ηD3(%))
𝑚𝑚𝑎𝑥
 (B.3) 
 
where  𝑚𝑚𝑎𝑥 is the maximum mass of vitamin D3 that can crystallize, 𝑚𝑓𝑒𝑒𝑑 is the vitamin mass that 
the system is fed up with, 𝑉𝐴𝑆 is the anti-solvent volume, 𝑆D3 is the solubility of vitamin D3 in 
acetonitrile, and ηD3,𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 is the corrected yield. 
 
  
 65 
 
Appendix C Configuration 1 – Recycle 
experiments 
 
C.1. Preparation of feed mixtures 
Like the methodology described for the Single cycle experiments (see Section 3.5.1), the 
Recycle experiments started with the preparation of mixtures composed by vitamin D3, solvent and 
anti-solvent. However, these mixtures were only prepared for a volumes ratio of 3 (see Table C.1). 
For theses mixtures, instead of 20 mg of vitamin, 75 mg were used to obtain a high amount of vitamin 
D3 crystals that could be later used for analysis. A filter with a higher surface area was used to avoid 
an increase in back pressure. 
 
Table C.1 Quantity of each compound for different mixtures with different anti-solvent/solvent volumes ratios. 
 
 At the end of Cycle 1, as mentioned in Section 3.5.2, the volume of the permeate stream was 
measured and then the stream was used for the preparation of the feed mixtures of Cycle 2. 
Considering the volume of the permeate stream, assumed to be the volume of acetonitrile, and the 
ratio under consideration, it was determined the solvent volume. After, the mass of vitamin D3 needed 
for the mixtures was calculated by applying equation 3.2 (see Section 3.5.1). The results for the feed 
mixtures of Cycle 2 of the two essays performed are presented in Table C.2. 
 
Table C.2 Quantity of each compound for different mixtures with different anti-solvent/solvent volumes ratios. 
Anti-solvent/Solvent 
volumes ratio 
Vitamin D3 
Concentration 
(mol L-1) 
Vitamin D3 
Mass (mg) 
Solvent 
Volume (mL) 
Anti-solvent 
Volume (mL) 
3 0.22 75 0.886 2.659 
Anti-
solvent/Solvent 
volumes ratio 
Assay 
Permeate 
stream 
Volume 
Solvent 
Volume 
Vitamin D3 
Mass 
Vitamin D3 
Concentration 
  (mL) (mL) (mg) (mol L-1) 
      
3 
Recycle 
experiment 1 
1.4 0.467 39.49 
0.22 
Recycle 
experiment 2 
1.6 0.533 45.13 
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C.2. Vitamin D3 results: mass quantity 
The mass of vitamin D3 obtained in different locations of the system for each cycle of the two essays performed is presented in Table C.3. The 
mass of vitamin obtained in the permeate stream that is recycled is determined by a mass balance of vitamin D3 in Cycle 1, and the mass of the feed 
mixture of Cycle 2 includes the vitamin D3 of the recycled stream and the one added to prepare the mixture (see Table C.2). 
 
Table C.3 Vitamin D3 mass obtained for the two-stage continuous crystallization performed under the following conditions: temperature of the first crystallizer, 40 ºC; 
mean residence time in the second crystallizer, 59 s; volumetric flow rate,15 mL h-1; mesh of the filter, 2 μm; configuration of the process, Configuration 1. 
   Mass of Vitamin D3 (mg) 
Anti-solvent/ 
/Solvent Ratio 
Essay Set-Point Mixture Pumped 
2nd 
Crystallizer 
Precipitate 
Filter Permeate 
3 
Recycle 
experiment 1 
Cycle 1 75.00 74.03 69.71 54.51 8.80 6.40 
Cycle 2 39.49 93.44 89.74 41.10 5.70 25.20 
Recycle 
experiment 2 
Cycle 1 75.00 74.34 72.94 43.04 19.50 10.40 
Cycle 2 45.13 88.15 83.15 46.70 12.70 19.80 
 
 According to the methodology presented in Section 3.5.2, the mass percentage of the vitamin in different locations of the system is calculated, 
which results are presented in Table 4.2 and the results concerning the absolute yield and filter efficiency are presented in Tables 4.3 and 4.4 (see Section 
4.1.2).  
 
 
 
